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ABSTRACT 
 
The controversy surrounding the findings that copy number variation (CNV), of the CCL3 encoding 
genes, influences HIV-1 infection and disease progression has been in part attributed to the variable 
results obtained from methods used for copy number evaluation. Like CCL3, the genes encoding the 
CC chemokine CCL4, also a natural ligand of the CCR5 receptor, are found to occur in population-
specific multiple copy number and have been shown to play a protective role against HIV-1. In this 
study, we evaluated the standard method of quantitative Real-Time PCR (qPCR) and Droplet Digital 
PCR (ddPCR) for CCL4L gene copy number determination. The CCL4 encoding genes are CCL4, occurring 
in two copies per diploid genome (pdg), and the non-allelic CCL4L genes, comprised of CCL4L1 and 
CCL4L2, which are both found in multiple copies pdg. Copy number of CCL4L, CCL4L1 and CCL4L2 was 
determined in a cohort of HIV-1-uninfected individuals from the South African Black (n=23) and 
Caucasian (n=32) population groups using qPCR and ddPCR, with the addition of another 30 black 
individuals to the ddPCR cohort. A stronger correlation between the number of CCL4L copies and the 
sum of CCL4L1 and CCL4L2 copies generated by ddPCR (r=0.99, p<0.0001) compared to qPCR (r=0.87, 
p<0.0001) was observed. Real-Time qPCR exhibited greater inaccuracy at higher copy numbers which 
is particularly relevant to our cohort of Black individuals who have a higher range of CCL4L copies (3-
6) compared to Caucasians (0-4) and a higher population median (4 and 2, respectively). Medians and 
ranges of CCL4L1 (Black: 2, 0-4, Caucasian: 0, 0-2) and CCL4L2 (Black: 2, 1-5, Caucasian: 2, 0-3) were 
also higher in the Black population. Droplet Digital PCR was shown to be a far superior method to qPCR 
for assessment of CCL4 gene copy number variation, the accuracy of which is essential for studies of 
the contribution of variable gene copy number to phenotypic outcomes of host infection and disease 
course. We further used the CCL4L copy number data to examine variation of these genes with 
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reference to measured stimulated CCL4 production by the same individuals. Although significant 
differences in the copy number range medians and patterns of distribution of the genes CCL4L1, 
CCL4L2 and combined CCL4L were observed between the two populations, on a whole, the two 
populations do not differ significantly with respect to CCL4 production. Caucasian females however 
had a higher level of protein production per copy of CCL4L than Black females. When stratifying 
production based on population specific copy number median, Black individuals showed a decreased 
level of protein production at a CCL4L copy number below the median, although this was not 
maintained when the CCL4L1 and CCL4L2 genes were analysed individually. CCL4 copy number and 
production data was compared to data generated for CCL3 in the same cohort. CCL4 chemokine levels 
were significantly higher in both the Black and Caucasian populations and Black individuals had a 
higher number of gene copies of the CCL3L genes giving rise to functional CCL3 protein than the CCL4L 
genes producing functional CCL4 protein. These results highlight genetic differences between 
divergent populations, differences in distribution of CCL4 and CCL3 encoding genes and protein 
production, and suggest an intricate regulation of the CCL4L encoding genes.  In order to investigate 
the role of CCL4 in HIV-1 control, we next assessed variation in the numbers of CCL4L copies in relation 
to CCL4 production in a cohort of 14 long-term nonprogressors (LTNPs).  While no associations 
between copy number and CCL4 production were observed, the LTNP cohort had significantly lower 
levels of CCL4 production than the HIV-1-uninfected cohort, and this was maintained when Black and 
Caucasian individuals were examined individually. When the LTNP cohort individuals were divided 
based on viral loads, individuals with viral loads <400 RNA copies/ml had significantly lower CCL4 
production than those with viral loads >400 RNA copies/ml. This finding suggests a role for the amount 
of CCL4 produced in the reduced pace of HIV-1 progression observed in LTNP individuals. Since genetic 
variation other than copy number can also influence CCL4 protein production, we then proceeded 
with a thorough genetic characterization of the CCL4 gene of uninfected individuals and investigated 
any possible relationships with select variants and CCL4 production.  Sequencing the complete gene 
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and flanking regions of 23 Black and 32 Caucasian revealed several intra as well as extragenic SNPs, 
with one newly identified SNP at position -1063. The Black population exhibited a higher degree of 
variability compared to the Caucasian population. We described four haplotypes in the Caucasian 
population, three haplotypes in the Black population, and a single haplotype shared between both 
population groups. Of the four indels that were identified, a three bp deletion (rs3216921) was the 
only indel present in the Caucasian population and was not identified in the Black population. Of all 
the indels, this indel had the highest allelic frequency (14%). Comparisons of haplotypes and prevalent 
SNPs with protein production in both population groups did not show any significant differences. 
Caucasian individuals harbouring the 3bp deletion however, had significantly higher levels of CCL4 
production (p=0.024). These results form a good base from which to further investigate the impact of 
select genetic variants on CCL4 production and possibly HIV-1 control. This study has succeeded in 
optimising a ddPCR assay for the copy number determination of the CCL4 genes and has interrogated 
the relationship between CCL4L copy number and CCL4 production in both HIV-1-uninfected 
individuals as well as a subset of LTNPs. The results suggest a complex, intricate regulation of CCL4 
that appears to play a role in HIV-1 control. In conclusion, this study forms the basis for future work 
to build on and to further explore the role of this CCR5 ligand in HIV-1 disease.  
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The first reported cases of Acquired Immune Deficiency Syndrome (AIDS), then an unidentified 
disease, were in 1981 (Gottlieb 1981; Gottlieb et al. 1981; Siegal et al. 1981).  The infectious agent of 
the disease was identified as a retrovirus (Barre-Sinoussi et al. 1983; Gallo et al. 1984; Popovic et al. 
1984) which was later named Human Immunodeficiency Virus (HIV) (Coffin et al. 1986).  Since then, 
the disease has become a global health pandemic and as early as 1987, the World Health Organization 
had set up a programme to probe the spread of the disease and  possible treatments and strategies 
to manage it (Mann 1987).  By pledging to work towards the Millennium Development Goals (MDG), 
compiled in 2000, the United Nations member states and several other organizations committed to 
working towards eight goals of international significance, one of them being to combat diseases such 
as HIV, and in 2001, the expected outcomes that were to be met with regards to improving the global 
scenario of HIV were clearly defined (UNAIDS 2013c).  
 
As the target date (2015) to reach the MDGs approaches, advances in spheres such as decreasing the 
number of new infections and increasing the number of individuals with access to treatment have 
been positive (Figure 1.1.1A and B). However, there are still an estimated 35.5 million people living 
with HIV worldwide, and 2.3 million new infections in adults and 260 thousand new infections in 
infants were reported in 2012 (Figure 1.1.1B) . The largest disease burden is borne by countries with 
low socio-economic climates, with Sub-Saharan Africa being the most affected (Figure 1.1.1C). South 
Africa in particular, has the highest infection rate and HIV prevalence in the world (Figure 1.1.1D and 
E).  
 
In 2009, for example, it was reported that while the rate of mother to child transmission of HIV was 
as low as 1% in developed countries, in some resource-poor African countries, the rate was as high as 
50% (Paintsil and Andiman 2009). While implementation of administration of treatment to HIV-
infected mothers can prevent mother-to-child transmission (MTCT), study of these mother and infant 
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pairs before the current recommended drug regimen have helped to elucidate possible host immune 
factors that contribute to the exposed uninfected phenotype which may be applied to studies 
investigating protection mechanisms seen in sero-discordant couples.  
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Figure 1.1.1 Infographic of HIV statistics (A) Reduction in new HIV infections in adults and children since 2001. (B) 2012 HIV statistics. (C) Heat map of people living with HIV 
in sub-Saharan Africa in 2013. (D) Percentage of individuals living with HIV and (E) proportion of HIV infections showing the contribution of individual countries to the total 
in 2013.  (UNAIDS 2013a; UNAIDS 2013b; UNAIDS 2014). 
2013
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 HIV TREATMENT: SUCCESSES AND CHALLENGES 
 
Highly Active Antiretroviral Therapy (HAART), a combination therapy of protease inhibitors, entry 
inhibitors, nucleoside and non-nucleoside reverse transcriptase inhibitors and integrase inhibitors 
(AIDSinfo 2014) has been a medical triumph as it has significantly increased the expected life-span of 
HIV-infected individuals as well as decreased the number of AIDS related deaths (Palella et al. 1998; 
Walensky et al. 2006). Even though there were some challenges in initiation of the roll out of HAART 
in South Africa, the therapy has been a success in both adults and children who are provided with the 
therapy, despite their low resource surroundings  (Coetzee et al. 2004; Reddi et al. 2007).  
 
HAART has been shown to not only effectively prevent free virus transmission to cells, but cell to cell 
transmission as well (Agosto et al. 2014).  Although one MDG was to provide treatment for 15 million 
HIV-infected individuals in 2015, by 2012, this quota was only met by 65% (Figure 1.1.1B). HAART, 
however is not a cure for HIV infection and has to be adhered to for a patient’s lifetime, as periods of 
non-adherence can result in increases in viral loads as viral reservoirs and latent viruses are not cleared 
from cells. Furthermore, the treatment has driven the evolution of drug resistant viral strains, is 
beyond the reach of many individuals in poor countries, and can lead to mild toxicities in patients, 
which might be a factor contributing to the increased occurrence of non-communicable diseases such 
as diabetes and liver disease, observed in HIV positive individuals  (Richman et al. 2009). 
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 HOST IMMUNE FACTORS AND GENETIC VARIABILITY 
 
The development of prophylactic therapies such as vaccines, have taken several different approaches. 
The difficulties faced in inducing neutralizing antibodies to HIV-1 and the variation observed within 
HIV envelope proteins motivated the change to a vaccine design that would induce a cellular response 
(Sekaly 2008). The STEP trial, which followed this design, however, failed to protect against HIV-1 
infection and in some cases exacerbated infection rates (Gray et al. 2010). The outcomes of the trial 
were in part attributed to previous immunity of the study participant to the adenovirus vector that 
was used (Gray et al. 2010). Furthermore, the macaque study, which prompted the testing of the STEP 
regimen in humans, revealed that protection in those animals may have been associated with specific 
Human Leukocyte Antigen (HLA) genotypes (Sekaly 2008).  The most successful HIV vaccine trial to 
date, the RV144 Thai trial, used a combination of two vaccines, a canarypox vector-based vaccine 
harbouring genetically engineered versions of three HIV-1 genes (env (envelope glycoprotein) , gag 
(Group Specific Antigen) and pol (polymerase)) and a second vaccine composed of genetically 
engineered gp120, which is an HIV-1 envelope protein subunit. This trial was estimated to offer 
protection against HIV-1 infection to 31% of study participants compared those who received the 
placebo; however the vaccine had no effect on viral set point in the vaccinated individuals that became 
infected (Donald and McNeil 2009). An interesting outcome of the trial however was that correlates 
of protection that were identified were not neutralising antibodies or cellular immunity, but likely to 
have included antibody-dependent cellular cytotoxicity (ADCC) antibodies, that is, antibodies that 
classically form part of an innate immune response (Donald and McNeil 2009). These examples all 
highlight that, to date, the factors which constitute a protective immune response to HIV-1 are still 
unknown, and that a better understanding of the immunology of HIV-1 infection is necessary for the 
design of more effective alternate therapies as well as immunogens for vaccine development.  
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It has been suggested that the extraction of the most knowledge from vaccine efficacy trials would 
need to include the examination of host immune responses, viral sequences (which includes 
identifying viral strains, in South Africa for example, HIV-1 subtype C is the prevalent circulating strain) 
as well as host genetics and  how these factors overlap and interact with/influence each other  over 
time (Tomaras and Haynes 2014) (Figure 1.2.1).  
 
Studying the genetic contribution to varying host immune factors in HIV-1 infection traditionally 
involves the determination of genetic variability, in the form of Single Nucleotide Polymorphisms 
(SNP) and insertions and deletions (indels) and the ways in which these naturally occurring variants 
may influence dynamics such as protein production, and how varying levels of production, in turn can 
influence the disease at several levels, ranging from acquisition to progression and disease 
attenuation. During the past few years however, gene copy number variation (CNV) has emerged as a 
factor that is responsible for a considerable component of the genetic variability that influences many 
diseases (Freeman et al. 2006; Wain et al. 2009).    
 
 
Figure 1.2.1 Schematic diagram of factors to be considered when assessing vaccine trial data (Tomaras and 
Haynes 2014). 
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A small group of individuals who become HIV-infected but manage to remain healthy, without the use 
of HAART for long periods of time, offer a unique opportunity to investigate the correlates of HIV-1 
protective immunity. Differences in host responses to HIV-1 infection, host genetic variation as well 
as differences in viral strains have been noted across the progression spectrum of HIV-1-infected 
individuals, ranging from rapid on the one side of the spectrum, to slow progression on the opposite 
end of the spectrum (Poropatich and Sullivan 2011). Broadly termed long-term nonprogressors 
(LTNPs) in this study, these individuals generally maintain normal CD4+ T cell counts, control viral 
replication and exhibit no clinical symptoms of disease, in the absence of antiretroviral therapy, for  
extended periods of time (up to 20 years) (Mikhail et al. 2003). The stringent criteria for the 
catergorisation of LTNPs are however not clearly defined and may differ from study to study. One 
observation was that viral copy numbers as well as viral mRNA expression in LTNP individuals are 
comparable to progressors just after seroconversion, suggesting that LTNPs differ from progressors in 
that they are able to maintain contol over viral replication (Vesanen et al. 1996).  After a few years, 
however, LTNPs do eventually start showing symptoms of progression (Lefrere et al. 1997; Rodes et 
al. 2004).  
  
Teasing out the host factors contributing to HIV-1 protection, requires a back to basics scientific 
approach which starts much earlier than the vaccine development stage to first establish baseline data 
in specific populations, i.e. first understanding these factors in an HIV-1 free backdrop, then 
elucidating the impact of possible changes/responses of these factors in the context of HIV-1 infection. 
Furthermore, these studies can provide insights into what possible, additional host responses should 
be looked at as potential contributers to vaccine trial outcomes.  
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Reported findings that African populations display the greatest genetic heterogeneity (Tishkoff et al. 
2009) compared to other populations, can be explained by the widely accepted theory that modern 
humans originated in Africa from where they migrated to other parts of the world approximately 150 
000 years ago (Seielstad et al. 1999). The intra-ethnic diversity as well as the ethnic diversity displayed 
in South Africa, combined with the fact that sub-Saharan African countries, more specifically South 
Africa, carry one of the highest HIV-1 disease burdens worldwide (UNAIDS 2014), emphasises the 
importance of conducting studies relating to HIV-1 protective immunity in these populations.  
 
Genetic variability in a number of genes, classified as AIDS restriction genes, was shown to influence 
cytokine regulation, viral entry into cells as well as modulation of innate and acquired immunity. These 
variants can result in full or partial resistance to HIV-1 infection or they may have an effect on disease 
progression in individuals who are already infected (O'Brien and Nelson 2004). Some of the genes that 
have been classified as AIDS restricting genes are those involved in viral entry.  
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 HIV-1 VIRAL ENTRY AND THE C-C CHEMOKINE RECEPTOR-5 (CCR5) 
 
The entry of HIV-1 into a variety of CD4+ host cells, including dendritic cells, T-helper cells, 
macrophages and monocytes, is not limited to the blood or sites of infection but also several organs, 
such as the brain and heart (Levy 2006).  In brief, the entry process begins with the  attachment of the 
virus to the cell membrane, facilitated by various virus and immune factors (Figure 1.3.1), followed by 
binding to the CD4 receptor (Dalgleish et al. 1984; Maddon et al. 1986). This involves a high affinity 
interaction of the trimeric gp120 peptide of the viral envelope glycoproteins (Env) to the CD4 receptor  
(McDougal et al. 1986) and is followed by a conformational change in the gp120 subunit, exposing its 
chemokine receptor binding region which binds to either the CXCR4 or CCR5 co-receptor (Deng et al. 
1996; Dragic et al. 1996) Thereafter, the virus and cell membrane fuse, forming a hairpin structure and 
the transmembrane gp41 is inserted into the host cell and  the virion released.  
 
Figure 1.3.1 Viral entry of HIV-1 into CD4+ cells. HIV-1 first attaches to cells (a) then binds to the CD4 receptor 
via the trimeric gp120 subunit of the Env protein (b). Followed by a conformational change in gp120 which 
facilitates binding to the co-receptor (c) either CXCR4 or CCR5. A hairpin loop is then formed and viral and host 
membrane fuse (d) (Shattock and Moore 2003). 
 
 
The CXCR4 receptor is utilised by T-cell-tropic or X4 strains of the virus while the receptor utilised by 
macrophage-tropic or R5 strains is CCR5.  Macrophage tropic HIV-1 is the major virus transmitted from 
person to person and is the predominant virus in the early stages of infection (Connor et al. 1997).   
v v
CCR5
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The CCR5 receptor has 7 transmembrane domains and is a member of the G-protein-coupled receptor 
family (Samson et al. 1996a). Due to its role in viral entry, CCR5 has been a point of interest in the 
design of HIV-1 therapies.  A 32 base pair (bp) deletion, CCR5Δ32, in the CCR5 gene, leading to a 
truncated protein that does not display receptor functionality has been shown to offer protection 
against HIV-1 in individuals who are homozygous or heterozygous for the mutation (Dean et al. 1996; 
Eugen-Olsen et al. 1997). This deletion only occurs at a frequency of 0.1% in Black South African 
individuals (Williamson et al. 2000).  However, many other SNPs have been reported in the CCR5 gene 
which influence HIV-1 disease in a variety of ways, and occur at different frequencies in different 
populations (Petersen et al. 2001), for example, an association between a SNP (G245A) and a longer 
time for virologic control by HIV-1 treatment was linked to African ancestry (Cheruvu et al. 2014).  
Many of the CCR5 SNPs have been described as belonging to specific haplotypes and some of these 
haplotypes have been associated with HIV-1 disease progression (Martin et al. 1998; Gonzalez et al. 
1999; Mummidi et al. 2000). Certain haplotypes, that were identified in multiple populations were 
found to have opposing effects depending on the population group in which they were present 
(Catano et al. 2011). 
  
 CC CHEMOKINES 
 
Chemokines are small immunoregulatory molecules which belong to different families (C, CC, CXC 
and CX3C chemokine families), based on the position of conserved cysteine residues in their amino-
terminus (Zlotnik et al. 2006)  A variety of receptors and their corresponding ligands belong to each 
family (Figure 1.4.1).  
The Role of CCL4 in HIV infection» Introduction 
 
 
 
 
12 
 
 
Figure 1.4.1 Schematic description of the structure of the different families of chemokines and the receptors 
and ligands which belong to the family (Rostene et al. 2007). 
 
Non-human primates have been a good research tool since the advent of the chimeric lentivirus (Lu 
et al., 1999). In vivo and ex vivo experiments showed that measured levels of chemokines, correlated 
with protection elicited by anti-Simian Immunodeficieny Virus (SIV) vaccines in macaques (Ahmed et 
al. 2005).  The role for innate immunity in protective immunity and outcome of infection was 
demonstrated using these models (Lehner et al. 1996; Ahmed et al. 1999; Ahmed et al. 2001).  
Complete or partial protection against SIV was seen in both naïve and vaccinated macaques who had 
high levels of production of CC Chemokines as well as CD8+ T-cell antiviral factors.  The production of 
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these chemokines is highly variable in naïve macaques and those exhibiting the highest levels of 
chemokine production were found to be included in the group that resisted a pathogenic SIVsm 
challenge after vaccination (Ahmed et al. 1999; Ahmed et al. 2001), suggesting that genetic or 
environmental factors may affect CC chemokine production.  Innate immunity may assist in generating 
HIV/SIV specific responses upon primary encounter with HIV/SIV. 
 
Cocchi et al. (1995) first demonstrated that the human CC chemokines, C-C motif chemokine ligand-3 
(CCL3) (macrophage inflammatory protein, MIP-1α), CCL4 (MIP-1β) and CCL5 (RANTES, regulation 
upon activation normal T expressed and secreted) were the major HIV-suppressive factors produced 
by CD8+ T cells.  CCL3, CCL4 and CCL5 were initially demonstrated to be the natural ligands of the CCR5 
receptor (Combadiere et al. 1996; Raport et al. 1996; Samson et al. 1996b) and later CCL8 (MCP-2, 
Monocytic chemotactic protein-2) was also identified as a CCR5 ligand (Blanpain et al. 1999). The 
protection offered by the CC chemokines has therefore been attributed to some or possibly a 
combination of all of the following proposed methods of hindering viral entry:  competitive binding 
between these ligands and R5 strains of HIV-1, to the CCR5 receptor; downregulation of the CCR5 
receptor; or, the induction of receptor dimerisation (Cocchi et al. 1995; Oravecz et al. 1996; Zagury et 
al. 1998; Vila-Coro et al. 2000).  Interestingly, although the chemokine MCP-3 binds to the CCR5 
receptor with a high affinity, it does not offer much protection against HIV-1, possibly because, as an 
antagonist of the receptor, downstream pathways after receptor binding would not be activated and 
CCR5 down-modulation would not occur (Blanpain et al. 1999). 
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 GENETIC STRUCTURE OF THE CCL3-CCL4 REGION OF CHROMOSOME 17 
 
The genes encoding both CCL3 and CCL4 are located on chromosome 17q21 (Irving et al. 1990; 
Hirashima et al. 1992). The multiple copy number, allelic isoforms of CCL3 and CCL4 (which each occur 
in two copies per diploid genome (pdg)), are believed to have resulted from a segmental duplication 
in this region of the chromosome (Menten et al. 2002; Modi 2004). Different population groups exhibit 
varying copy number ranges and mean gene copy numbers (Colobran et al. 2008) and these genes fall 
within a group of genes that have been identified as being most stratified by copy number in different 
populations (Sudmant et al. 2010). While the contribution of CCL3 to HIV-1 disease progression as well 
as to mother-to-child HIV-1 transmission has been extensively investigated, the same cannot be said 
about the role of CCL4 in HIV-1 disease (Shostakovich-Koretskaya et al. 2009). The understated 
possible significance of CCL4 has been suggested to be as a result of failure of studies to separately 
study, for example, CNV in the C-C motif chemokine ligand 4-like 1 (CCL4L1) and CCL4L2 genes 
(Shostakovich-Koretskaya et al. 2009). Collectively termed CCL4L, these non-allelic isoforms share a 
95% sequence similarity with CCL4 and can be distinguished from each other by a SNP within an 
acceptor splice site in intron two, giving rise to aberrantly spliced products of CCL4L2 that do not seem 
to display classical CCL4 functionality (Colobran et al. 2005) (Figure 1.5.1). The mature, functional 
protein product produced by CCL4L1 however, differs from its isoform CCL4, by just one amino acid 
(Howard et al. 2004; Colobran et al. 2005). These two proteins are therefore not easily differentiated 
from each other in vitro when using monoclonal antibodies currently available. Functional CCL4 is 
secreted by a number of cell types, such as monocytes, T and B lymphocytes, NK cells, dendritic cells 
as well as neutrophils, and participates in the immune response through its chemoattractant 
properties, directing various cell types to sites of inflammation (Menten et al. 2002).  
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Although the CCL3L and CCL4L genes are located on the same segmental duplication, there are several 
break points in this region, which means that the genes will not necessarily occur in the same copy 
number (Cardone et al. 2008).  While CNV of these two genes showed a positive correlation in a 
Ukrainian population, CCL3L occurred at higher copy numbers than CCL4L (Shostakovich-Koretskaya 
et al. 2009). Using the paralogue ratio test (PRT) to asses CCL3L copy number, Walker et al. (2009) 
showed that the combined copy number of CCL3L1 and CCL3L3 (i.e. the CCL3-like genes that produce 
a functional CCL3 protein and excluding CCL3L2, the truncated CCL3 gene) was equal to the copy 
number of CCL4L in a Caucasian population group, however this direct relationship between CCL3L 
and CCL4L has not been unequivocally proven for populations with very high copy numbers, like 
African population groups. Interestingly, a study conducted by Aklillu et al. (2013), using both the PRT 
method and fluorescence in situ hybridization (FISH) with probes to validate copy number calls at 
higher copy numbers, showed that sub-Saharan Africans display “heterogeneity in CCL3L1 repeat 
structure not yet observed in Europeans” and points out that more research into the structural 
variation at this locus needs to be undertaken.  
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Figure 1.5.1 Schematic representation of the CCL4 encoding genes and transcripts. (a) The genes located within 
the 17q11.2-q12 and amplification of the region containing the CCL3 and CCL4 encoding genes (b). The CCL4 and 
CCL4L1 gene give rise to transcripts with the same functionality while the CCL4L2 gene which harbours a 
mutation (‘G’ allele) in the second intron gives rise to aberrantly spliced products (c) (Colobran et al. 2010).  
 
 CONTRIBUTION OF CCL3 AND CCL4 GENE COPY NUMBER AND GENETIC VARIANTS TO     
HIV-1 DISEASE  
 
While several studies have  shown a protective anti-HIV-1 effect of a higher copy number of the genes 
CCL3L1 (Townson et al. 2002; Meddows-Taylor et al. 2006; Kuhn et al. 2007; Shalekoff et al. 2008; 
Shostakovich-Koretskaya et al. 2009) and CCL4L1 (Shostakovich-Koretskaya et al. 2009), other studies 
have failed to replicate these results (Bhattacharya et al. 2009; Urban et al. 2009), leading to much 
controversy in the field (Field et al. 2009; He et al. 2009; Shrestha et al. 2009). Possessing copies of 
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CCL4L1 only, (that is, no copies of CCL4L2), has been  associated with higher levels of CCL4 mRNA 
production compared to individuals who possessed copies of CCL4L2 only and no copies of CCL4L1 
(Colobran et al. 2005). A different study suggested that possessing copies of CCL4L2 only but no copies 
of CCL4L1, led to faster progression to AIDS of HIV-1 infected Ukrainian children (Shostakovich-
Koretskaya et al. 2009). These two results however, have not been replicated by others (Shao et al. 
2007). Furthermore, the combination of an individual’s CCL3L and CCL4L copy number has also been 
suggested to be functionally relevant (Shostakovich-Koretskaya et al. 2009).  Experiments conducted 
in lipopolysaccharide stimulated monocytes have found a correlation between copy number of CCL3L 
and CCL3 production suggesting that it is likely that CCL3L copy number may have an effect on CCL3 
production in vivo (Townson et al., 2002).  In a MTCT study, it was demonstrated that lower levels of 
foetal CCL3 associated with an increased risk of intrapartum-acquired HIV-1 infection (Meddows-
Taylor et al. 2006). However, further genetic characterisation of these genes, in the hope of developing 
a genotypic assay to test for increased risk of infection or a more rapid disease progression, has to be 
carried out because copy number could only partially explain the observed phenotype, suggesting that 
those infants that did become infected have non or less functional copies of the gene (Gonzalez et al. 
2005; Meddows-Taylor et al. 2006). This may be a result of mutations in some of the copies of CCL3L 
or even in the two copy CCL3 gene, which would explain why there may not always be a direct 
association between actual copy number and protection, but rather an association between 
protection and specific population median (Gonzalez et al., 2005). A SNP in CCL5 (28G), for example, 
was associated with delayed disease progression, most likely through increased expression of CCL5 
(Liu et al. 2004). Serum levels of CCL5 however remained the same in the presence or absence of the 
mutation. Several SNPs identified across the CCL3 and CCL4-encoding genes in both European 
populations and those of African ancestry were associated with a faster progression to AIDS (Modi et 
al. 2006).   As mentioned above, CCL3L did not completely account for the increased expression of 
CCL3 in infants in an MTCT study (Meddows-Taylor et al. 2006) however, a later study also conducted 
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on the same African infants, suggested that copy numbers of CCL3L1 above the population specific 
median offered protection against acquiring HIV-1 infection in infants but this association was not 
maintained when mothers took a dose of nevirapine or if their viral loads were low (Kuhn et al. 2007).  
 
The role of increased CCL3 and CCL4 production in LTNP individuals as well as highly-exposed 
seronegative individuals (HESN) is to date poorly understood. A study following commercial sex 
workers in Benin found that individuals who were uninfected had higher serum levels of CCL3 and 
CCL4 than those that became infected over time (Lajoie et al. 2010), but at the mucosa this was not 
mimicked, suggesting that perhaps recruitment of CD4+ cells to the mucosa might facilitate infection 
but having them high in the blood is good to prevent infection. Interestingly, it has been suggested 
that chemokine production may be influenced by hormones, which means that production levels may 
differ between males and females (Barrenäs et al. 2008).  
 
 In a recent study conducted in our laboratory, the contribution of CCL3L copy number to CCL3 
production in two ethnically divergent (Black and Caucasian) South African populations was 
investigated (Picton et al. 2013). The study revealed that despite the significant differences in CCL3L 
copy number, no difference in CCL3 production was noted between the two population groups upon 
in vitro stimulation of isolated peripheral blood mononuclear cells (PBMCs), and in addition, no 
correlation between CCL3 production and CCL3L copy number was noted in either the Black or 
Caucasian cohort (Picton et al. 2013). 
 
The contradictory findings of association studies between copy number variation and HIV-1 protection 
have been, in part, attributed to the variability of assays used to determine gene copy numbers, such 
as the quantitative Real-Time PCR (qPCR) TaqMan assay, which displays low accuracy at higher copy 
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numbers. Thus, an accurate and easily implementable copy number determination assay for 
populations of African origin is needed. 
The recently developed technique of droplet digital PCR (ddPCR) involves emulsification of the 
amplification reaction into thousands of small droplets, allowing PCR amplification to take place in 
each droplet. The droplets are subsequently assessed for fluorescence (TaqMan chemistry), indicative 
of a positive end-point PCR. This technique has proven to generate accurate results in a number of 
applications (Henrich et al. 2012; Heredia et al. 2013; Strain et al. 2013), including copy number 
determination of the CCL3-encoding genes (Hindson et al. 2011). 
  
 RATIONALE FOR CURRENT STUDY 
 
Taking all the above into consideration and with the aim of trying to understand the relationship 
between variable copy number-encoded chemokines and chemokine production, ddPCR for copy 
number determination will be assessed in the CCL4L-encoding genes, CCL4L1 and CCL4L2, to compare 
the same TaqMan assay in two different platforms, qPCR and ddPCR, using the BioRad QX100 system. 
The CCL4L-Taqman assay (Shostakovich-Koretskaya et al., 2009) that will be implemented in this study 
has an intrinsic validation in that CCL4L copy number = CCL4L1 copy number + CCL4L2 copy number, 
and thus the accuracy of the two methods is easily evaluated. 
 
Folllowing copy number determination, the data will be used to investigate the relationship between 
CCL4L copy number and CCL4 protein production in two genetically divergent (Black and Caucasian) 
South African populations free of HIV-1 infection, since HIV-1 infection in itself impacts significantly 
on CCL4 production as well as on the production of a number of other chemokines.  Since the same 
two populations cohorts were previously studied by Picton et al (2013), with respect to CCL3 
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production and CCL3L copy number, we will be able to compare and jointly analyse the two datasets.  
In addition, having access to a small cohort of HIV-1-infected LTNPs, will allow a preliminary 
comparison of CCL4 gene copy number variation and protein production between these interesting 
individuals and the HIV-1-uninfected cohort individuals.  Lastly, genetic variation, in terms of SNPs and 
indels in the two copy pdg, CCL4 gene in HIV-1 uninfected South African Black and Caucasian 
individuals will be investigated and these variations and putative haplotypes will be assessed for their 
contribution to CCL4 protein production.  
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 STUDY OBJECTIVES 
 
The specific objectives of this study are thus to: 
i. Evaluate a copy number determination assay of the CCL4L genes on the platforms of qPCR and 
ddPCR  
ii. Determine differences in copy number distribution between two HIV-1-uninfected, ethnically 
divergent South African populations of Black and Caucasian individuals 
iii. Assess CCL4 protein production and the influence of CCL4L copy number on production in the 
two populations 
iv.  Compare CCL4L copy number distribution, CCL4 production levels as well as the influence of 
copy number variation on production in the context of HIV-1-infection in a cohort of long-
term nonprogressors 
v. Describe genetic variability within the CCL4 gene in the HIV-1-uninfected cohort and assess 
the influence of these variations on CCL4 production 
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CHAPTER 2 MATERIALS AND METHODS 
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 COHORT DESCRIPTION 
 
2.1.1. HIV-1-uninfected individuals 
Copy number variation of the genes CCL4L, CCL4L1 and CCL4L2, CCL4 protein production as well as 
genetic variants in CCL4 were investigated in a previously well studied cohort of  55 HIV-1-uninfected 
volunteers (Picton et al. 2012a; Picton et al. 2012b; Lassauniere et al. 2013; Picton et al. 2013; 
Shalekoff et al. 2013), consisting of 23 South African Black and 32 South African Caucasian individuals. 
The Black cohort comprised 9 males (39.1%) and 14 females (60.9%) with a mean age of 36.7 years 
(range: 23-62 years). The Caucasian cohort comprised 11 males (34.4%) and 21 females (65.6%) with 
an average age of 40.5 years (range: 25-67 years). There were no significant statistical differences in 
the ages and male:female ratio between the Black and Caucasian cohorts (Mann-Whitney P=0.2674 
and Fishers’ exact test P=0.7808, respectively).  
2.1.2. Additional samples for CCL4L copy number determination 
An additional cohort of 30 HIV-1-uninfected Black females, recruited as controls in a previous study 
that investigated mother-to-child transmission of HIV-1, was used to increase the number of study 
participants in the Black cohort for the determination copy number variation of CCL4L by Droplet 
Digital PCR (ddPCR). 
2.1.3. Long-term nonprogressor (LTNP) cohort 
CCL4 production and copy number variation was also investigated in a cohort of 14 LTNPs. 
Requirements for the inclusion into this cohort were maintenance of stable CD4+ T cell counts >350 
cells/µl and a viral load <20 000 RNA copies/ml for more than 5 years in the absence of antiretroviral 
treatment, at the time of the study. These individuals were prospectively recruited and disease 
progression will be continually followed to observe whether they maintain these criteria, as some 
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individuals have not been HIV-1-infected >10 years, the time span for which some studies state an 
infected individual should remain asymptomatic for in order to be classified as an LTNP.  
 
The LTNP cohort consisted of ten Black and four Caucasian individuals. Measurements of viral load 
and CD4+ T cell count for the LTNP individuals are shown in Table 2.1.1.  The median age of the Black 
LTNPs was 40.5 years (range: 33-54 years) and comprised four (40%) males and six (60%) females. 
Among LTNPs, three individuals (LTNP6, LTNP7 and LTNP13) met the criteria of elite controllers, i.e. 
patients with plasma HIV RNA levels of <50 copies/ml (Pereyra et al. 2008).  
Table 2.1.1 Characteristics of HIV-1-infected long-term nonprogressor study participants 
Patient ID Lab ID 
Age 
(years) 
Sex 
Viral load 
(copies/ml) 
Log10 
(viral 
load)1 
CD4+ T cell 
count 
(cells/μl) 
Time since 
diagnosis 
(years) 
Black South Africans (n=10) 
LTNP1 TG1 38 M 6 070 3.78 334 9 
LTNP2 TG2 47 F 5 780 3.76 400 6 
LTNP3 TG4 35 M 183 2.26 910 9 
LTNP4 TG7 54 M 23 300 4.37 968 4 
LTNP5 TG9 46 F <400 2.60 327 9 
LTNP6 TG11 32 F <40 1.59 693 7 
LTNP7 Pru1 54 F <40 1.59 >2000 14 
LTNP8 Pru2 43 M 1 155 3.06 637 14 
LTNP9 Pru3 36 F 1 410 3.15 775 11 
LTNP10 Pru4 38 F 124 2.09 379 13 
Caucasian South Africans (n=4) 
LTNP11 TG3 53 M <400 2.60 877 5 
LTNP12 TG5 33 F 5 420 3.73 396 5 
LTNP13 TG8 67 M <40 1.59 811 6 
LTNP14 TG10 40 M <400 2.60 327 18 
1Where viral load was determined to be <40 or <400 RNA copies/ml, Log10 (viral load) was determined for values of 39 and 
399, respectively. 
Pink shaded LTNPs are considered to be Elite Controllers. 
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For each of the above cohorts, written informed consent was obtained from the participants at the 
time of enrolment and ethical approval was provided by the Human Research on Human Subjects 
Committee of the University of the Witwatersrand (Appendix D: Ethical Clearance Certificate). 
 
 PERIPHERAL BLOOD MONONUCLEAR CELL (PBMC) ISOLATION AND CULTURE  
 
Fresh whole blood was collected from the cohort of 55 HIV-uninfected individuals as well as the 14 
LTNP individuals in tubes coated with ethylenediaminetetraacetic acid (EDTA) as an anticoagulant. 
PBMCs were isolated by centrifugation of the blood on Ficoll-Plaque Plus (GE Healthcare, Sweden) 
using standard methods. Plasma was removed and stored at -80°C for future studies. Harvested cells 
were counted using a haemocytometer and resuspended in RPMI (Roswell Park Memorial Institute) 
medium (Gibco, Invitrogen, Paisley, UK) supplemented with 10% foetal bovine serum (Gibco, 
Invitrogen, Paisley, UK) at concentrations of 2 x 106 cells/ml. Cells were aliquoted into 24-well tissue 
culture plates (Corning, NY, USA) (1.4 x 106 cells/well) and one half of the wells (variable depending 
on amount of PBMCs isolated) were left unstimulated while the rest of the cells were stimulated by 
the addition of the plant mitogen, phytohaemagglutinin (PHA) at a final concentration of 12.5 μg/ml.  
Plates were incubated for 20 hours overnight at 37 °C in 5% CO2.  Following incubation, cells were 
pelleted by centrifugation and supernatants (harbouring the secreted CCL4) were collected and stored 
at -80°C until further analysis.  Cell pellets were also stored at -80°C for genomic DNA extraction. 
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 DNA EXTRACTION 
 
Total genomic DNA for use in CCL4L copy number determination by quantitative Real-Time PCR (qPCR) 
and for CCL4 genetic characterisation, was extracted from fresh EDTA-anticoagulated whole blood 
samples using the QIAmp DNA Blood Mini Kit (QIAGEN, Dusseldorf, Germany), and stored at -20°C for 
periods >1 year prior to use.  
 
For genotyping using ddPCR, DNA was extracted using the same kit, from previously isolated and 
frozen PBMC pellets (isolation described above, 2.2.).  The qPCR assay was the standard method for 
copy number determination in our laboratory, and the CCL4L qPCR assays were carried out prior to 
the acquisition of the Bio-Rad QX100 ddPCR system. It was therefore not possible to use the same 
DNA for both assays as the DNA used for qPCR had also been used for a number of other genotypic 
assays and experiments (as already mentioned, this is an extensively studied cohort) and it was 
therefore necessary to re-extract DNA from stored PBMCs processed at the same time as the initial 
DNA extractions from blood. To exclude the possibility of DNA quality interfering with the PCR in the 
qPCR assays, we further assessed DNA, extracted and stored in the same way as used in qPCR testing, 
from the additional cohort of 30 Black individuals, by ddPCR. 
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 GENE NOMENCLATURE 
2.4.1. CCL4L nomenclature 
The term CCL4L refers collectively to the genes CCL4L1 and CCL4L2, which are non-allelic isoforms of 
CCL4 (Gene ID: 6351). Various sources (Colobran et al. 2005; Shostakovich-Koretskaya et al. 2009) 
concur that on chromosome 17, the sequence of the CCL4 encoding genes begins with CCL4, followed 
by the aberrantly spliced CCL4L gene and then by the functional CCL4L gene (Figure 2.4.1). The CCL4L 
genes, however, are differently named in different studies, with some sources referring to the 
upstream gene as CCL4L1 and the downstream copy as CCL4L2, while others refer to the variable copy 
number gene immediately downstream from CCL4 as CCL4L2 and the gene downstream from CCL4L2 
as CCL4L1.  In the current study, the naming of the genes will follow the latter, in concordance with 
the annotation updated in GenBank (Benson et al. 2006) in June 2014 and in the study by Colobran et 
al. (2005). The aberrantly spliced CCL4L gene which is immediately downstream from CCL4 will 
therefore be referred to as CCL4L2 (Gene ID: 9560) while the fully functional CCL4L gene, downstream 
from CCL4L2 will be referred to as CCL4L1 (Gene ID: 388372). These genes are schematically depicted 
in Figure 2.4.1. The study by Shostakovich-Koretskaya et al. (2009), from which the assay used to 
determine CCL4L copy number was adapted, uses a nomenclature in which ‘1’ and ‘2’ are replaced by 
‘a’ and ‘b’ respectively, based on the sequence of genes on the chromosome as well as gene 
functionality (Figure 2.4.1). The alphabet naming system will be maintained for comparisons involving 
CCL3L gene copy number.  
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Figure 2.4.1 Schematic representation of the relative position, order and different nomenclature of the CCL3 
and CCL4 encoding genes on chromosome 17q12. 
 
2.4.2.CCL3L nomenclature 
The qPCR assay employed by Picton et al. (2013) was adapted from that described by Shostakovich-
Koretskaya et al. (2009). The CCL3L genes consist of CCL3L1 (Gene ID: 6349), CCL3L2 (Gene ID: 390788) 
and CCL3L3 (Gene ID: 414062).  Since both CCL3L1 and CCL3L3 encode functional proteins (CCL3L), the 
two isoforms cannot be separately detected or quantified (or distinguished from CCL3 produced by 
the two copy pdg gene, namely CCL3 (Gene ID: 6348)) by standard immunological techniques, and are 
collectively referred to as CCL3La (Figure 2.4.1). CCL3Lb is the name that has been assigned to CCL3L2, 
which has been referred to as a ‘pseudogene’ that does not produce the standard functional protein 
(Shostakovich-Koretskaya et al. 2009). 
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 COPY NUMBER DETERMINATION ASSAYS 
 
In addition to determining copy number variation of the CCL4L genes in our cohorts, the methods of 
qPCR and ddPCR were compared to identify the method that was most efficient and more appropriate 
for our populations. 
2.5.1. TaqMan primers and probes 
Primers and probes used to detect the CCL4L genes by qPCR and ddPCR were as published by 
Shostakovich-Koretskaya et al. (2009) and are capable of distinguishing the two genes, i.e. CCL4L1 and 
CCL4L2. Four minor groove binder (MGB) probes were used for targeting the genes CCL4L (fluorescent 
label: 6-carboxyfluorescein (FAM)), CCL4L1 (fluorescent label: FAM), CCL4L2 (fluorescent label: VIC) 
and the betaglobin gene (BGB, fluorescent label: VIC), which served as an endogenous control, were 
used for qPCR. 
 
In addition to the probes mentioned above, a FAM-labelled BGB probe with the same sequence as the 
VIC-labelled BGB probe was used for ddPCR, as each PCR reaction contained both a gene-specific and 
an endogenous control primer/probe set (i.e. duplex reactions). The PCR reaction to assess copy 
numbers of the CCL4L2 gene using a VIC-labelled probe, therefore, also included a FAM-labelled BGB 
probe, while FAM-labelled CCL4L and CCL4L1 were assessed together with a VIC-labelled BGB probe.    
2.5.2.Evaluation of gene copy numbers by quantitative Real-Time PCR 
A qPCR assay as described by Shostakovich-Koretskaya et al (2009) was used to assess copy numbers 
of the genes CCL4L, CCL4L1 and CCL4L2 in the cohort of 55 HIV-uninfected individuals. In this method, 
standard curves of CT (threshold cycle) values against log [DNA, ng] were generated for each of the 
four probes (CCL4L, CCL4L1, CCL4L2 and BGB) from duplicate reactions for six doubling dilutions of 
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genomic DNA (25ng to 0.78ng) extracted from K562 and A431 cell lines (ATCC, Manassas, VA, USA), 
having two copies of CCL4L1, and two copies of CCL4L and CCL4L2, respectively. BGB was used as an 
internal control as it is known to occur in two copies pdg.  Duplicate wells of each sample were run for 
each of the four probes. The TaqMan Universal Master Mix (Applied Biosystems, Foster City, CA, USA) 
was added in all reactions, together with 5 ng of sample DNA.  
 
The quantity of initial template present for each sample was determined by comparing generated CT 
values to the standard curves of the respective genes. Copy number is the ratio of the template 
quantity for the gene of interest to the template quantity for the endogenous control (BGB), multiplied 
by two.  
 
Copy number values were determined for each test replicate and the mean of these values 
determined. If the standard deviation between replicates was >10% relative to the replicate mean, 
copy number quantitation was repeated in duplicate, irrespective of whether the sum of CCL4L1 and 
CCL4L2 did not equal CCL4L. The mean copy number value was rounded to the nearest integer. If the 
result was ambiguous, that is, if gene copy number happened to fall on a decimal of around 0.5, the 
qPCR was repeated for that sample. PCR was conducted in an Applied Biosystems 7500 Real-Time PCR 
system (Applied Biosystems, Foster City, CA, USA).   
2.5.3. Evaluation of gene copy number using the Droplet Digital PCR system 
For ddPCR, a double digest was performed on DNA with the restriction enzymes BamHI and SacI 
(Promega, Madison, Wisconsin, USA) for two hours at 37°C, followed by heat-inactivation of the 
restriction enzymes for 20 minutes at 65°C. To select which restriction enzymes to use in the digests, 
reference gene sequences of CCL4L1 and CCL4L2 were downloaded from GenBank (Benson et al. 
2006). Sequencher version 4.5 sequence analysis software (Gene Codes Corporation, Ann Arbor, MI 
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USA http://www.genecodes.com) was used to align primer and probe sequences to the genes. 
Restriction enzymes with cutting sites flanking the amplified and probed gene region, and with similar 
reaction conditions, were selected.  This step is essential to ensure proper target fragmentation for 
the tandem, syntenic copies of the CCL4L genes. 
 
Reaction mixtures (20 μl) containing 75 ng of digested sample DNA, ddPCR Supermix for probes (Bio-
Rad, Hercules, CA, USA), 1000 nM of each primer and 200 nM of each probe were loaded into the 
QX100 Droplet Generator together with 70 μl droplet oil as per the manufacturer’s instructions. Post 
droplet generation, the oil/reagent emulsion was transferred to a 96-well plate (Eppendorf AG, 
Hamburg, Germany) and the samples were amplified on the conventional Bio-Rad T100 Thermal 
Cycler (95°C for 10 minutes, followed by 40 cycles of 94°C for 30 seconds and 60°C for 60 seconds, 
with a final elongation step of 98°C for 10 minutes). The plate, containing the droplet amplicons, was 
subsequently loaded into the QX100 Droplet Reader (Bio-Rad, Hercules, CA, USA). Standard reagents 
and consumables supplied by Bio-Rad were used, including, cartridges and gaskets, droplet generation 
oil and droplet reader oil.  
 
Reactions for each sample were run in triplicate for each gene, CCL4L, CCL4L1 and CCL4L2.  Each 
reaction well contained a gene-specific target as well as an endogenous control target PCR (BGB), in a 
duplex reaction.  
 
In the QX100 Droplet Reader, individual droplets are counted as positive or negative based on the 
presence or absence of fluorescence of the DNA molecules that are enclosed within the droplets. 
These readings are then compared to the count obtained for BGB, which is known to occur as two 
copies pdg. The number of gene copies present is determined by the QuantaSoft Software version 
1.2.10.0  (Bio-Rad, Hercules, CA, USA) by applying Poisson statistics to the fraction of end-point 
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positive reactions (Hindson et al. 2011). The average number of droplets generated in each reaction 
was 11 946.  This method was used to generate CCL4 copy number data for the cohort of 55 HIV-1-
uninfected individuals and a further 30 Black individuals as well as the cohort of 14 LTNPs. 
 
For ddPCR, since the standard deviation between replicates was <10% for all but one sample, we 
decided to apply more stringent criteria and repeated samples (in triplicate) on the rare occasion 
(3/55) that the sum of the copy number of CCL4L1 and CCL4L2 was not equal to the copy number of 
CCL4L (see below). 
2.5.4.PCR amplification and sequencing of CCL4L of select individuals 
Since samples that presented with unusual copy number patterns in the ddPCR assay were in the low 
copy number range and were maintained upon repetition, we decided to investigate further. To 
validate the presence of the CCL4L genes in these samples, primers were designed (Same method of 
primer design and amplification used as described in 2.8.1.) (fwd: 5’ GCAGTCTATCAGTCAATGGT 3’, 
rev: 5’ CACATCACCTCTAACAGC 3’) to amplify the CCL4L genes collectively by conventional PCR 
(Expand High Fidelity PCR System, Roche, Mannheim, Germany).  
 
Positive amplifications were indicative of the presence of CCL4L, however to determine whether 
CCL4L1, CCL4L2 or both genes were present, amplicons were sequenced (sequencing methodology 
and analysis explained below in 2.8.2. and 2.8.3.). Sequencing data were analysed at the single SNP 
position (rs4796195), that distinguishes the two genes (Colobran et al. 2005) and  possible SNPs in the 
binding sites of primers and probes used for the TaqMan assays, which may have contributed to the 
unexpected copy numbers detected by ddPCR, were investigated. 
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 CCL4 PRODUCTION ANALYSIS  
 
Quantification of CCL4 in unstimulated and PHA-stimulated PBMC supernatants from the HIV-1-
uninfected cohort as well as the LTNP cohort, was performed by sandwich enzyme-linked 
immunosorbent assay (ELISA; DuoSet ELISA Development Systems: R&D systems, Minneapolis, MN, 
USA). Reactions were carried out in triplicate following methods prescribed by the manufacturer. The 
minimal detectable levels were <10 pg/ml. A standard curve was generated using a duplicate doubling 
serial dilution (1000-15.625 pg/ml) of the CCL4 standard and this was used to calculate the CCL4 
concentration of samples based on mean optical density, which was measured using the Oragnon 
Teknika Microwell System Reader. Plasma samples were assessed undiluted, while the unstimulated 
supernatants and the stimulated supernatants were diluted by factors of 10 and 100, respectively.  
 COMPARISON OF CCL4 AND CCL3 PRODUCTION AND COPY NUMBER VARIATION 
 
Data generated for CCL4 and its encoding genes by the methods described above were compared with 
CCL3 raw data generated by and analysed in detail by Picton et al. (2013) in the same cohort of 55 
HIV-uninfected individuals. CCL3 and CCL4 production data were both determined by ELISA as 
described above (2.6), under the same conditions at the same time point.  
 
For the quantitation of CCL3, supernatants from PHA-stimulated cells were diluted by a factor of 1000 
(Picton et al. 2013). Copy number variation of the CCL3L genes, however, was assessed using 
quantitative Real-Time (qPCR) unlike CCL4L copy number variation which was measured using ddPCR. 
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Raw CCL3 copy number and production data generated and analysed by Picton et al (unpublished) in 
the same cohort of 14 LTNPs was used to investigate differences between CCL3 and CCL4 production 
and the influence of copy number variation on chemokine production in these individuals. 
 GENETIC CHARACTERISATION OF THE CCL4 GENE 
2.8.1. PCR amplification of CCL4 
An alignment of the CCL4, CCL4L1 and CCL4L2 reference sequences, obtained from GenBank, was 
generated using DNAMAN phylogenetic software (Version 4.0, Lynnon Biosoft, Pointe-Claire, Quebec, 
Canada) and was used to design PCR primers to amplify the CCL4 gene. Designing primers based on 
this alignment was necessitated by the fact that the CCL4 and CCL4L genes share such a high sequence 
similarity, and it was therefore necessary to ensure that the primers designed selectively amplified 
the CCL4 gene alone and not the CCL4L genes.  Primer design was further complicated by the fact that 
many regions in which the CCL4 and CCL4L genes differed significantly, were unsuitable due to the 
formation of DNA secondary structures. The limited choice of suitable regions in which to pick primers, 
led to a large 4.7 kb fragment that included the core promoter region of the gene, the 5’ and 3’ 
untranslated regions (UTR), the complete gene (exons 1, 2 and 3 and introns 1 and 2) and well as 
regions upstream and downstream from the elements mentioned, being amplified by two sets of 
overlapping primers (Table 2.8.1).   
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Table 2.8.1 Primer pairs used for the amplification of the CCL4 gene using the Expand High Fidelity PCR System 
 
 Sequence Fragment Size Annealing Temperature^ 
 CCL4 
Fragment 
1 
Forward 5’ CATGTTGCCCAGTCTGGTATCG 3’ 
2514bp 
 
Set 1: 60 
Reverse 5’ GGTCATCTGGCTTTATCCTTTGCAT 3’ Set 2: 65 
CCL4 
Fragment 
2 
Forward 5’ GTTAGGTGGGAATGGATATTTGG 3’ 
3010bp 
Set 1: 60 
Reverse 5’ CTGAGGAATAGGATGTGTGCAC 3’ Set 2: 60 
^ The Expand High Fidelity PCR System recommended cycling conditions involve two sets of denaturation, annealing and 
elongation cycles within the initial denaturation and final elongation steps. Annealing temperatures for each of the two sets 
are indicated. 
 
Putative primers selected from the alignment, were analysed using the program GeneRunner (version 
3.05, Hastings Software Inc, http://generunner.net/) to determine whether they met optimal 
suggested primer design standards and were subsequently tested for specificity using Primer-Blast (Ye 
et al. 2012) to confirm that there was no specificity to the CCL4L genes or any other regions of the 
genome.  
 
Standard PCR was carried out using the Expand High Fidelity PCR system (Roche, Mannheim, Germany) 
and cycling conditions were as recommended by the manufacturer. DNA extracted from whole blood 
samples from the cohort of 55 HIV-1-uninfected individuals (2.3) was used to amplify CCL4. 
2.8.2.Sequencing 
All PCR amplicons were purified using the QIAquick PCR Purification Kit (Qiagen, Dusseldorf, 
Germany). Sequencing reactions, utilising overlapping primers that were designed for specific 
fragments, were carried out using BigDye Terminator version 3.1 (Applied Biosystems, Foster City, CA, 
USA) and electrophoresed on the automated 3100 Genetic Analyzer (Applied Biosystems).  
(Sequencing primers are listed in Appendix A). 
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2.8.3. Sequencing analysis 
Sequences were assembled using Sequencher version 4.5/5.3 sequence analysis software (Gene 
Codes Corporation, Ann Arbor, MI USA http://www.genecodes.com) and chromatographs were 
analysed individually for identifiable SNPs.   
 
An alignment of individual sequences as well as the CCL4 reference sequence (GenBank) was 
generated using Sequencher Software, in order to identify homologous nucleotide substitutions.  Any 
polymorphic positions identified within the amplified region were viewed using the NCBI Sequence 
Viewer (version 3.6) and if they had been previously identified, SNP information and accession 
numbers were obtained from Database of Single Nucleotide Polymorphisms (dbSNP, Bethesda (MD): 
National Centre for Biotechnology Information, National Library of Medicine. dbSNP accession: 
rs143457996– rs17617372, (dbSNP Build ID: 142 );Available 
from: http://www.ncbi.nlm.nih.gov/SNP/).    
2.8.4. Assigning the wild type (WT) allele 
It was assumed that the ancestral allele or WT allele was the most prevalent allele detected and if 
there were discrepancies between the two population groups, the allele most prevalent in the Black 
population was assigned as the WT. In cases where it was still unclear, alignment to the Pan 
troglodytes sequence (Gene ID:  454593, GenBank) was used to determine the ancestral allele.   
2.8.5. Haplotype prediction/analysis 
For the prediction of haplotypes in both the Black and Caucasian populations, the SNP/indels across 
the CCL4 gene were analysed both visually as well as by using Haploview software (version 4.2) 
(Barrett et al. 2005) to determine linkage disequilibrium (LD) between genetic variants. Linked SNPs 
with r2> 0.6 were considered to be part of the haplotypes we described.  
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2.8.6.Characterization of putative insertions/deletions  
Four putative indels were identified in regions in which chromatograms indicated two different 
templates. In many cases, these fragments were resequenced to eliminate the possibility of a mixed 
template. Reverse PCR primers were designed for each indel, to generate sequence information after 
the point of the indel to the next sequencing primer. (indel primers are listed in Appendix A) 
2.8.7.Hardy-Weinberg equilibrium 
Haploview software is also able to generate Hardy-Weinberg deviation values and was used to 
assess polymorphisms in each of the population groups independently.   
2.8.8.Bioinformatic tools used 
The CCL4 mRNA sequence (NM_002984.3) was obtained from Genbank and analysed with Sequencher 
Software. The first frame protein translation displayed by Sequencher was checked against the 
published CCL4 protein sequence to evaluate what amino acid changes would result from exonic SNPs 
identified. These changes were investigated using Poly-Phen 2 (prediction of functional effects of 
human non-synonymous SNPs data base) Software  (Adzhubei et al. 2010) to predict the 
structural/functional consequences of specific amino acid changes detected. 
 
 STATISTICAL ANALYSIS 
The ages and male: female ratio of the South African Black and Caucasian cohorts were compared 
using the nonparametric Mann-Whitney test and the Fishers’ exact test respectively. Correlations 
between the copy number of CCL4L and the combined copy numbers of CCL4L1 and CCL4L2 were 
calculated using the two-tailed Pearson’s test. All statistical analyses were performed using GraphPad 
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Prism version 4.02 for Windows (GraphPad Software, San Diego California USA, www.graphpad.com). 
P values <0.05 were considered significant. 
 
Fisher’s exact test and non-parametric Mann-Whitney U-tests comparisons were used to determine 
differences in copy number distribution and CCL4 protein production levels between study groups. 
Correlations between copy number and production were also calculated using GraphPad Prism 
version 4.02.  The same statistical software and analyses were used in the comparison of copy number 
and production data generated for CCL3 in the uninfected and LTNP cohorts.  
 
Allelic and haplotype frequencies of SNPs within the CCL4 genes were calculated using Microsoft Excel 
2013 (Microsoft, USA) and Haploview software was used to calculate deviations from Hardy-Weinberg 
equilibrium, as well as LD r2 and D’ values. Where LD was not complete between SNPs in respective 
haplotypes, calculation of haplotype frequencies only included individuals who had all SNPs within the 
haplotype.   
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CHAPTER 3 RESULTS 
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 COMPARISON OF QPCR AND DDPCR FOR CCL4L COPY NUMBER DETERMINATION 
 
3.1.1. Assay validation 
When comparing the qPCR and ddPCR techniques for CNV determination, the CCL4L genes are ideal 
because CNV can be generated for CCL4L1 and CCL4L2 individually as well as for the collective CCL4L 
genes as a total. The correlation of CCL4L gene copy number to the sum of CCL4L1 and CCL4L2 
therefore, serves as a good way to validate the accuracy of the results generated from either assay.  
While the correlations for both methods assessed in this study showed a significant positive deviation 
from zero (p value<0.0001, Figure 3.1.1A), the data generated from the unrounded results (raw data) 
of ddPCR were found to show a stronger correlation (r=0.991) than that of the qPCR assay (r=0.869). 
The strong correlations generated by comparing copy number data generated by ddPCR are 
maintained as the copy number of CCL4L and the sum of CCL4L1 and CCL4L2 increase (Figure 3.1.1Aii). 
It is, however, evident when examining the correlation generated by qPCR that the accuracy of the 
assay decreases as the copy number increases (Figure 3.1.1Ai). In fact, when copy numbers were 
stratified into two groups (0-3 and >3) and correlations determined separately, it was found that at 
copy numbers 0-3, data generated by both qPCR and ddPCR had strong correlations (r=0.88 and 
r=0.96, respectively; p’s<0.0001, ), however at copy numbers >3, the qPCR data had a very weak 
correlation (r=0.44; p=0.057), while the ddPCR data maintained a very strong correlation (r=0.99; 
p<0.0001), highlighting the weakness of qPCR at high copy numbers. This is a major shortfall of the 
method, especially when investigating African populations, in which copy number ranges and means 
of the CCL4L genes (Range: 3-6, median: 4, Table 3.1) were found, as previously reported (Colobran et 
al. 2008), to be higher compared to Caucasian individuals (Range: 0-4, median: 2, Table 3.1). 
Percentage PCR efficiencies for all three primer sets were calculated to be >92%. 
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Figure 3.1.1 Concordance between CCL4L copy number and the sum of the copy number of CCL4L1 and CCL4L2 
generated by two assays. (A) Scatter plots of unrounded average copy number data generated using (Ai) 
quantitative Real-Time PCR and (Aii) Droplet Digital PCR. (B) Numbers in the coloured blocks indicate the number 
of individuals in which the rounded off CCL4L copy number was equal to the sum of CCL4L1 and CCL4L2, and 
numbers in the blocks that are clear indicate instances where they were not equal. Data was generated using 
two different assays, that is, (Bi) quantitative Real-Time PCR assay and (Bii) Droplet Digital PCR. The adjacent 
table shows the copy numbers obtained for the individuals that did not fall within the shaded blocks in the ddPCR 
assay. 
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0 4 4
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Table 3.1.1 Population specific medians and ranges generated by qPCR and ddPCR for the South African Black 
and Caucasian populations 
 
 
 
 
When samples were assessed using qPCR, there were 22 individuals in which the combined rounded 
copy number of CCL4L1 and CCL4L2 did not equal to the copy number generated for CCL4L (n=53, 
Figure 3.1.1Bi). This was observed in just two individuals assayed with ddPCR and one additional 
individual presented with an unusual copy number pattern (n=55, Figure 3.1.1Bii). Upon repetition of 
these three samples, the same results were obtained and qPCR data suggested that there were 0 
copies of the CCL4L genes in these individuals. To further investigate this, the CCL4L genes of the three 
individuals were subsequently PCR amplified and sequenced. The 0 copy number of CCL4L found in 
individual CCR04 (copy number pattern 0, 1, 0 for CCL4L, CCL4L1 and CCL4L2, respectively) was found 
to be a result of a homozygous SNP in the CCL4L probe binding site, which would result in failure of 
the probe to bind in the CCL4L reaction resulting in an incorrect ‘0’ copy number call.  Sequencing data 
confirmed that individual CCR17 (copy number pattern 1, 0, 0 for CCL4L, CCL4L1 and CCL4L2, 
respectively), did in fact have a CCL4L1 gene and attributed the 0 copy number result to a 3’ end 
homozygous SNP in the CCL4L1 reverse primer binding site. The copy number patterns for CCR04 and 
CCR17 were therefore confirmed to be 1, 1, 0 for CCL4L, CCL4L1 and CCL4L2, respectively. Although 
the qPCR for CCR04 and CCR17 was repeated a number of times and averaged out to 0 copies for both 
these individuals, when the raw data was re-examined, there were some repeats that yielded the 
same copy number pattern seen with ddPCR, however, these were not consistently seen in the 
majority of the repeats. 
  Black Caucasian 
  qPCR ddPCR qPCR ddPCR 
CCL4L 4 (2-7) 4 (3-6) 2 (0-4) 2 (0-4) 
CCL4L1 2 (1-4) 3 (1-5) 2 (0-3) 2 (0-3) 
CCL4L2 3 (0-7) 2 (0-4) 0 (0-5) 0 (0-2) 
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Interestingly, no SNPs were identified in the primer and probe binding regions of CCR52 (copy number 
pattern 0.5, 0.25, 0.25 for CCL4L, CCL4L1 and CCL4L2, respectively). However, the presence of both 
the genes CCL4L1 and CCL4L2 was confirmed. It is speculated that this individual may have a SNP in a 
primer or probe binding site of the BGB reference gene. If this is the case, considering that gene copy 
number of the CCL4L genes are generated relative to BGB, the estimated copy number would be less 
than expected but as observed, would maintain the correct gene ratio, that is, the same number of 
CCL4L1 and CCL4L2 genes are present in individual CCR52.       
 
DNA samples that had been extracted from whole blood and stored for several years were used for 
qPCR whereas freshly extracted DNA from PBMC’s was used for ddPCR. To rule out the possibility of 
DNA quality contributing to the results we further tested DNA, extracted and stored in the same way 
as used in qPCR testing, from an additional cohort of 30 Black individuals and assessed these by ddPCR. 
A 100% correlation between the copy number of CCL4L and the sum of CCL4L1 and CCL4L2 was 
observed (r=0.996, p<0.001, Figure A in Appendix B).   
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Figure 3.1.2 Clustering of unrounded average copy number values for all three CCL4L genes generated by 
quantitative Real-Time PCR and Droplet Digital PCR around whole integer copy numbers. Blue circles represent 
copy numbers generated by qPCR and green circles represent copy numbers generated by ddPCR. Y-axis: 
unrounded values. X-axis: integer values. 
 
3.1.2. Reproducibility of results 
Out of a cohort of 55 individuals genotyped by the qPCR assay, repeats had to be performed on 87.3 
% of individuals (48 samples) - when percentage deviations between replicates were greater than 10% 
compared to the replicate mean. Out of the 55 samples amplified using ddPCR, only 5.5% (3 samples) 
had to be repeated due to suspected inaccuracy, and only a single sample showed a standard deviation 
of above 10%. Additional repeats had to be carried out on samples assayed with qPCR as inter-
experimental variation was often observed for individual samples, suggesting a low reproducibility of 
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unresolved and there were often ambiguities in the data when decimals of 0.5 were observed, as it 
was unclear whether to round up or round down to the nearest integer. Standard deviations between 
repeats, generated by ddPCR, were below 10%, except on one occasion where the copy number reads 
for the three repeats of the CCL4L1 gene were 0.85, 1.10, 1.01 and could therefore easily rounded off 
to 1. When comparing unrounded average copy number values generated by the two methods, those 
generated by ddPCR showed a tighter clustering to the whole copy number values than those 
generated by qPCR (Figure 3.1.2).  
 
The data from qPCR were generated by relative comparison to a standard curve which means that if 
the R-squared value of the standard curve is low due to experimental error, the data from the entire 
plate is unusable. The ddPCR method measures absolute quantifications and generation of a standard 
curve is not necessary. 
 
Figure 3.1.3 Copy number frequencies of the sum of genes CCL4L1 and CCL4L2. Copy number frequencies were 
determined using two different methods in the South African (A) Black and (B) Caucasian populations. Green 
bars represent ddPCR while blue bars represent quantitative real-time PCR. 
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3.1.3. Population specific medians 
While the same copy number medians were calculated for the Caucasian cohort regardless of method 
used (2, 2, 0 for CCL4L, CCL4L1 and CCL4L2 respectively, Table 3.1.), and just a single difference in the 
copy number ranges was observed  (CCL4L2 gene: a maximum of 5 versus a maximum of 3), the 
inability of this assay to accurately deal with higher copy numbers was again reiterated when 
examining the medians and ranges in the Black individuals (Table 3.1.1, median copy numbers using 
qPCR 4, 2, 3 and 4, 3, 2 using ddPCR for CCL4L, CCL4L1 and CCL4L2 respectively).  Furthermore, the 
frequency distribution of the sum of CCL4L1 and CCL4L2, generated by both methods, follows a similar 
pattern of distribution around the population median when results from the Caucasian population are 
observed (Figure 3.1.3B), while the pattern of distribution differs substantially in the Black population 
when the two methods are compared (Figure 3.1.3A). The individual gene correlations between the 
copy numbers generated by ddPCR and qPCR were higher in the Caucasian population compared to 
the Black population (Supplementary Figure A).  
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 CCL4L COPY NUMBER ANALYSIS 
 
Due to the efficiency of ddPCR to determine CNV, copy number data generated by this method was 
carried through for CCL4L distribution analysis and used to compare with CCL4 production levels.  
3.2.1.Gender and copy number distribution 
Since there was no significant difference in CCL4L copy number between males and females in the 
HIV-1-uninfected Black cohort, an additional 30 HIV-1-uninfected female individuals were added to 
the Black sample group to increase the cohort size, thereby allowing the determination of a more 
accurate representation of copy number distribution for the Black South African population group. 
Upon reassessment of the data including the 30 additional females, a significantly higher number of 
copies of CCL4L was observed in Black female individuals compared to Black male individuals (p=0.003, 
Figure 3.2.1A) but the number of CCL4L1 and CCL4L2 genes did not differ significantly between the 
two groups (Figures 3.2.1B and 3.2.1C). There was however a trend (p=0.073) of higher representation 
of CCL4L2 in Black females compared to black males (Figure 3.2.1C), suggesting that this gene was the 
major contributor to the overall significant higher CCL4L copy number in Black females vs. males. 
 
Figure 3.2.1 Gender differences in copy number distribution between Black South African females and males 
for the (A) CCL4L genes, (B) CCL4L1 and (C) CCL4L2 individually. P values and number of participants are 
indicated.  
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3.2.2.CCL4L copy number variation between the Black and Caucasian population 
groups 
As expected and reported in other studies, significant differences were observed between the copy 
number distribution of the genes CCL4L, CCL4L1 and CCL4L2 between the two populations (Figure 
3.2.2).  Copy number medians and ranges for both genes individually and collectively, in both 
populations were previously reported (Table 3.1.1), however with the addition of the 30 additional 
individuals to the Black cohort, the population median and ranges of the genes CCL4L (range: 3-8, 
median: 4), CCL4L1 (range: 0-5, median: 2) and CCL4L2 (range 0-6, median: 2) shifted slightly from 
ranges and medians for CCL4L, CCL4L1 and CCL4L2 that were originally determined in the ddPCR assay 
development (medians: 4, 3, 2 for CCL4L, CCL4L1 and CCL4L2 respectively).  Figure 3.2.3 provides a 
graphical representation of the copy number distribution in the Black and Caucasian cohort and 
indicates the frequency of different copy number combinations. It is interesting to note that compared 
to Black individuals, just a single Caucasian individual had a CCL4L2 copy number of two, and the rest 
of the individuals in the cohort possessed either one or no copies. Similarly, just a single Caucasian 
individual had a CCL4L1 copy number of 3 while others had either 0, 1 or 2 CCL4L1 copies in contrast 
to the Black cohort, in which multiple individuals had higher copies of CCL4L1 and CCL4L2. 
 
When we compared the relationship between CCL4L1 and CCL4L2 copy number, there was an inverse 
correlation between the copy number of CCL4L1 and CCL4L2 in the Black population (p<0.001, Figure 
3.2.4A), that is, the more copies of CCL4L2 an individual has, the fewer copies of CCL4L1 they have. 
This relationship was not observed in the Caucasian population (p=0.194, Figure 3.2.4B). 
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Figure 3.2.2  Copy number variation of the CCL4L genes in the South African Black and Caucasian populations. 
Black individuals display significantly higher copies of (A) CCL4L, (B) CCL4L1 and (C) CCL4L2 compared to 
Caucasian Individuals. P values and number of participants are indicated.  
 
Figure 3.2.3 Differences in distribution and frequency of CCL4L copy number and CCL4L1 and CCL4L2 copy 
number combinations in HIV-1-uninfected (A) Black (n=53) and (B) Caucasian (N=31) South African cohorts. 
Circles represent the number of copies of CCL4L present, which equals to the sum of the number of copies of 
CCL4L1, represented by the open circles, and CCL4L2, represented by the shaded circles. Green squares 
represent the percentage frequency at which the various combinations occur in the two populations.    
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Figure 3.2.4 Inverse significant correlation between CCL4L1 and CCL4L2 copy numbers in (A) Black but 
not in (B) Caucasian individuals. P and r values are indicated, as well as line equation where correlation 
is significant. 
 
 CCL4 PROTEIN PRODUCTION AND CORRELATION TO COPY NUMBER 
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difference in CCL4 production was observed between the females of the two populations when 
unstimulated production data was analysed (p=0.579, data not shown). CCL4 production between 
Black individuals and Caucasian individuals of similar ages did not vary significantly (<35: p=0.183, ≥35 
p=0.905, data not shown). 
 
 
Figure 3.3.1 No Significant differences in CCL4 protein production in two South African populations 
but Black females have a higher PHA-stimulated CCL4 production than Caucasian females. CCL4 
production from PBMC supernatants (Ai) prior to PHA stimulation and (Aii) post stimulation in the Black 
and Caucasian populations were compared. Higher levels of PHA-stimulated CCL4 production were 
observed in (Bi) Black females compared to Caucasian females) but there was no significant difference 
in protein production between (Bii) Black and Caucasian males. P values and number of participants are 
indicated. 
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3.3.2.Correlation of CCL4 production with CCL4L copy number  
Having a copy number of CCL4L1 above the population median has been associated with protection 
against HIV-1 infection (Shostakovich-Koretskaya et al. 2009). When we compared the copy number 
of the CCL4L genes to unstimulated and PHA-stimulated CCL4 production for each population group, 
as well as the two groups combined, we failed to observe any significant correlations between 
production and copy number (PHA-stimulated protein production and CCL4L copy number 
correlations are represented in Figure 3.3.2). Subsequently, PHA-stimulated production levels below, 
above and equal to the population medians were examined (Figure 3.3.3). In the Black population, 
individuals with a CCL4L copy number less than the population median (median=4), displayed 
significantly lower PHA-stimulated CCL4 production than those with the median number of copies 
(p=0.018; Figure 3.3.3Ai). However, comparison of individuals with a CCL4L copy number less than the 
population median to those with CCL4L copies above the median, did not show a significant difference 
(p=0.300; Figure 3.3.3Ai). Also, compared to individuals with a median copy number, individuals with 
CCL4L copy numbers above the median did not have higher CCL4 production, in fact, the median CCL4 
production was lower above the median copy number than at the median copy number, although not 
significantly lower (p=0.408; Figure 3.3.3Ai). Interestingly, when comparing copy number of CCL4L1 
and CCL4L2 to CCL4 production in the Black population, although not statistically significant, inverse 
distributions or patterns were observed (Figures 3.3.3Aii and 3.3.3Aiii) compared to the CCL4L vs. CCL4 
production comparison. For both CCL4L1 and CCL4L2, lower production at the median copy number 
was observed compared to copy numbers below or above the median.    
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Figure 3.3.2 Correlations of PHA-stimulated CCL4 production to (i) CCL4L, (ii) CCL4L1 and (ii) CCL4L2 copy 
number variants in (A) Black and (B) Caucasian South African cohorts.  P and r values are indicated. 
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Figure 3.3.3 PHA-stimulated CCL4 production relative to population specific median copy numbers in two 
South African populations. In Black individuals, (Ai) CCL4L, (Aii) CCL4L1, (Aiii) CCL4L2 copy numbers below, equal 
to and above the population specific medians, indicated on the figures, were compared to CCL4 production. 
CCL4 production is significantly lower below the median of 4 copies of CCL4L (Ai) In Caucasian individuals, CCL4 
production below, equal to and above (Bi) the population median CCL4L copy number as well as below or equal 
to/above the population specific copy number medians for (Bii) CCL4L1 and (Biii) CCL4L2 are shown. P values are 
indicated.       
 
Figure 3.3.3Bi represents the distribution of CCL4 production at, below and above the median for the 
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of these two genes individually and collectively, in Caucasian individuals, did not reveal any significant 
differences or distribution patterns. 
3.3.3.CCL4 production per CCL4L copy number 
Assuming an equal contribution of the two copies pdg CCL4 genes to CCL4 protein production, the 
relationship of CCL4L, CCL4L1 and CCL4L2 copy number was compared with CCL4 production in an 
alternative way. We analysed the amount of PHA-stimulated CCL4 produced per gene copy number 
by dividing the CCL4 production data generated per individual by the copy number of each respective 
gene (i.e. CCL4L, CCL4L1 and CCL4L2; Figure 3.3.4). Individuals with zero copies of CCL4L, CCL4L1 or 
CCL4L2 were therefore not included in this analysis. While the Caucasian population group had a 
significantly higher level of stimulated CCL4 production per CCL4L gene copy than the Black population 
group (Figure 3.3.4A; p=0.0183), this was not maintained when production per CCL4L1 and CCL4L2 
copies were analysed individually (Figures 3.3.4B and 3.3.4C, respectively). Due to the significantly 
large CNV between the two population groups (with Caucasians having significantly lower copy 
numbers in all three genes (Figure 3.2.2)), and the fact that the CCL4 production did not differ between 
the two population groups (Figure 3.3.1Aii), it was not surprising that Caucasian individuals had 
increased CCL4 production per copy of CCL4L since the denominator (CCL4L copy number) is smaller 
in this group. The non-significant results for CCL4L1 and CCL4L2 analysed in the same manner however 
were more interesting. Next, to correct for the influence of the denominator, individuals from both 
populations groups, with either 3 or 4 copies of CCL4L and similar patterns of CCL4L1 and CCL4L2 
distribution, were compared for protein production per copy of CCL4L, in order to establish whether 
the same number of genes present would have different effects on CCL4 production. Results showed 
that no significant differences were seen in either population (Figure 3.3.5; p=0.890). 
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Figure 3.3.4 PHA-stimulated CCL4 production (pg/ml) per gene copy number of the CCL4L encoding genes in 
the Black and Caucasian South African population. The Black population has a significantly lower level of CCL4 
production per (A) CCL4L gene copy, but the two populations did not differ greatly in the amount of CCL4 
produced per copy of (B) CCL4L1 and (C) CCL4L2. P values and number and sample size are indicated. 
 
 
 
Figure 3.3.5 Comparison of PHA-stimulated CCL4 production per CCL4L gene copies in Black and Caucasian 
individuals having equal number of copies of CCL4L and comparable patterns of distribution of CCL4L1 and 
CCL4L2. 
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3.3.4.Comparison of CCL3L and CCL4L gene copy number and CCL3 and CCL4 
production 
i.  CCL3L and CCL4L copy number distribution 
 
Given that CCL3 and CCL4 are encoded by genes that are found closely clustered together in the 17q12 
region of chromosome 17, and that in European (Caucasian) populations it is believed that CCL3L and 
CCL4L copy numbers correlate very strongly, having access to CCL3 copy number and protein 
production data for the same cohort of 55 HIV-uninfected individuals, allowed us to investigate the 
relationship between these two chemokines.  Significant positive correlations of CCL3L and CCL4L gene 
copy number (Figure 3.3.6Ai; p<0.0001) and CCL3La and CCL4L1 copy number were observed in Black 
individuals (Figure 3.3.6Aii; p=0.025). There was however no significant correlation between CCL3Lb 
and CCL4L2 (Figure 3.3.6Aiii). The correlations of the same genes were all significantly positive and 
stronger in the Caucasian cohort (Figure 3.3.6Bi; p<0.0001; Figure 3.3.6Bii; p<0.0001 and Figure 
3.3.6Biii; p=0.003). 
 
Since CCL4L1 and CCL3La encode functional CCL4 and CCL3 proteins respectively, copy number 
distribution of these genes was compared in the Black South African cohort and although these gene 
copy numbers do significantly positively correlate (Figure 3.3.6 Aii), CCL3La copy number was found 
to be significantly higher than CCL4L1 copy number (Figure 3.3.7A, p<0.0001). In the Caucasian 
population, however, no significant difference was observed (Figure 3.3.7B), not surprising given the 
stronger correlation between these two genes in the Caucasian population group compared to the 
Black population group (Figure 3.3.6Bii/Biii; r=0.817 vs. r=0.467, respectively). 
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Figure 3.3.6 Correlation of CCL3L and CCL4L copy numbers generated in individuals of the same cohorts of 
South African (A) Black and (B) Caucasian individuals. Correlations of (i) CCL3L and CCL4L; (ii) CCL3Lb and 
CCL4L1, which encode protein forms that do not display classical CCL3 or CCL4 functionality; and (iii) CCL3La and 
CCL4L2, which encode functional isoforms of CCL3 and CCL4, are represented. P and r values are indicated and 
line equations when correlations are significant. CCL3L data provided by Picton et al. (2013). 
 
Figure 3.3.7 Comparison of the copy number distribution of the CCL4L1 and CCL3La genes (functional isoforms 
of the CCL4 and CCL3 genes, respectively) in a South African (A) Black and (B) Caucasian cohort. P values and 
number of participants are indicated. 
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ii.  CCL3 and CCL4 protein production 
The correlation of CCL4 and CCL3 protein production was investigated separately in each of the 
population groups as well as in the groups combined (Figure 3.3.8). Results showed that in the Black 
population, correlation of PHA-stimulated CCL3 and CCL4 production did not reach significance (Figure 
3.3.8B; p=0.119), and it is interesting to note that the copy numbers of the CCL4L2 and CCL3Lb genes 
also did not significantly correlate in this population group (Figure 3.3.6Aiii). In contrast, when 
correlations between PHA-stimulated CCL3 and CCL4 production were examined in the Caucasian 
population, there was a significant strong correlation (Figure 3.3.8C, p=0.0001). Analysing the 
relationship of the two proteins in the combined population (Figure 3.3.8A) also showed a significant 
positive correlation (p=0.001).  
 
 
Figure 3.3.8 Correlations of CCL4 production to CCL3 production in a cohort of (A) 55 HIV-1-uninfected 
individuals comprising of (B) Black and (C) Caucasian cohorts. P values and r values are indicated; and line 
equations where p values are significant. CCL3 production data was generated by Picton et al. (2013). 
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higher than CCL3 production in both unstimulated and PHA-stimulated PBMCs in all three categories 
(Figure 3.3.9).  
 
 
Figure 3.3.9  CCL3 and CCL4 protein production measured from (A) unstimulated PBMC supernatants and (B) 
PHA-stimulated supernatants, were compared in the cohort of (i) 55 HIV-1-uninfeced South Africans, 
comprising of (ii) 23 Black and (iii) 32 Caucasian individuals. P values are indicated.  
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 CCL4 AND HIV-1-INFECTED LONG-TERM NONPROGRESSORS (LTNPS) 
3.4.1.CCL4 copy number and production comparisons between uninfected Black 
individuals and Black LTNPs 
Since copy number distribution of the CCL4L genes was found to differ between the uninfected Black 
and Caucasian groups, comparisons of copy number distribution between the uninfected cohort and 
the cohort of LTNPs also had to be stratified by race. The Caucasian LTNP group however, only 
consisted of four individuals. Comparison of CCL4L, CCL4L1 and CCL4L2 copy number was performed 
between the HIV-1 uninfected Black population group and the Black LTNPs only, and as can be seen 
in Figure 3.4.1, no significant differences were observed in all three comparisons. Furthermore when 
we looked at the correlation of copy number of the CCL4-encoding genes and CCL4 production in the 
9 Black LTNPs, similarly to what we saw in the uninfected Black and Caucasian populations, there were 
no significant correlations in all three correlations performed (Figures 3.4.2A, B and C).   
 
 
Figure 3.4.1 Neither (A) CCL4L, (B) CCL4L1 nor (C) CCL4L2 copy number distribution differed significantly when 
a cohort of HIV-1-uninfected Black individuals was compared to a cohort of LTNPs. P values and number of 
individuals is indicated.    
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Figure 3.4.2 CCL4L gene copy numbers do not correlate with CCL4 production in a cohort of 10 Black South 
African LTNPs.  
 
3.4.2. CCL4 production in LTNPS differs from HIV-1-uninfected individuals 
One individual in the Black LTNP cohort displayed CCL4 production levels that were much higher than 
the rest of the cohort (Figures 3.4.3Ai and Bi, labelled outlier) and was therefore excluded from 
analyses when population groups were investigated individually. When comparing CCL4 protein 
produced by both unstimulated and PHA-stimulated PBMCs of LTNPs and HIV-1-uninfected 
individuals, we found that the total LTNPs (Black and Caucasian) produced significantly lower CCL4 
levels compared to the total uninfected cohort (unstimulated production: Figure 3.4.3Ai; p=0.007; 
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Figure 3.4.3Bii; p=0.011) and Caucasian cohorts (unstimulated: Figure 3.4.3Aiii; p=0.019; PHA-
stimulated: Figure 3.4.3Biii; p=0.008) were compared individually. Interestingly when similar 
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CCL3 production did not differ significantly when whole cohorts were compared as well as when 
divided based on race (Picton et al, unpublished data). 
 
 
Figure 3.4.3 CCL4 production from (A) unstimulated and (B) PHA-stimulated peripheral PBMCs isolated from 
HIV-1-uninfected individuals and LTNPs. P values generated from comparisons between an (i) HIV-1-uninfected 
cohort and a cohort of LTNPs were calculated with both the inclusion of the production level data of an outlier, 
indicated in figure, and excluding the outlier (p values in red). Comparisons of uninfected and LTNP individuals 
stratified on race, that is, (ii) Black and (iii) Caucasian were conducted, excluding the outlier data from the Black 
LTNP group. 
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individually. This higher level of CCL4 production compared to CCL3 production has also been reported 
in other studies. However, in the case of LTNPs, unstimulated and PHA-stimulated CCL3 and CCL4 
protein levels in the two populations do not significantly differ (Figure 3.4.4A, p=0.0663, Figure 3.4.4B, 
p=0.135, respectively). Furthermore, CCL3 and CCL4 protein production displays a strong positive 
correlation in LTNP individuals (Figure 3.4.5, p<0.0001) and although positive, the correlation between 
CCL3 and CCL4 was not significant in the uninfected Black cohort (Figure 3.3.6B). 
 
 
Figure 3.4.4 No significant differences in (A) unstimulated and (B) PHA-stimulated CCL3 and CCL4 production 
from peripheral PBMCs. P values and number of individuals are indicated. CCL3 production data was generated 
by Picton et al (unpublished). 
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Figure 3.4.5 Correlation of PHA-stimulated CCL4 and CCL3 production in a group of HIV-1-infected LTNPs 
(n=14). CCL3 production data was generated by Picton et al (unpublished). 
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with respect to chemokine production (i.e. CCL4 and CCL3), revealed that it is the less than 400 RNA 
copies/ml LTNPs that are the lower protein producers in both the unstimulated and PHA-stimulated 
scenarios, with significance in the unstimulated CCL4 and PHA-stimulated CCL3 and CCL4 comparisons 
(Figures 3.4.6Ai, Bi and Bii). The LTNPs having VLs greater than 400 RNA copies/ml, did not differ in 
either CCL3 or CCL4 production compared to their corresponding uninfected cohort (Figure 3.4.6). 
 
Figure 3.4.6 Comparisons of (i) Unstimulated and (ii) PHA-stimulated (A) CCL3 and (B) CCL4 production 
between HIV-uninfected Black South Africans and HIV-infected Black LTNPs. Comparisons of LTNPs are further 
stratified into individuals with viral loads below and above 400 RNA copies/ml. P values and sample size are 
indicated. Note, in Bi and Bii an outlier had been removed from the total LTNP group, i.e. n=9, whereas in Ai and 
Aii (CCL3), the outlier in included in the corresponding group. 
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 GENETIC CHARACTERIZATION OF THE CCL4 GENE 
 
3.5.1. Single nucleotide polymorphisms 
Amplification and sequencing of the CCL4 gene in the HIV-1-uninfected cohort allowed for the 
identification of a number of genetic variants. In total, 77 SNPs were identified in a 4.7kb fragment 
containing the CCL4 gene, in a cohort of Black and Caucasian individuals. Sixty-six SNPs in the CCL4 
gene and its flanking regions were identified in Black South African individuals while in the Caucasian 
population, 38 SNPs were identified. Of these, only 22 and 12 SNPs were identified within the 
transcribed region of the CCL4 gene (i.e. excluding promoter and flanking regions) in Black and 
Caucasian individuals respectively. SNP position, nucleotide changes and minor allelic frequencies are 
indicated in Table 3.5.1. Exons, introns and UTRs are also indicated in Table 3.5.1 and the adjoining 
Figure 3.5.1A, which schematically represents CCL4 gene structure.  The percentage of SNPs unique 
to each population group as well as the overlapping percentages are indicated in Figure 3.5.1B. 
   
From the alignment of the 55 generated sequence assemblies to the CCL4 reference sequence and its 
flanking regions retrieved from GenBank (Benson et al. 2006), the major allele from all SNPs was 
designated as the WT allele.  
 
There was a single SNP locus at which the minor allele frequency was high in the Black South African 
group (45.65%; rs116657123, Table 3.5.1; position 663). In this case, even though one allele (G) was 
slightly in the majority, just to be certain, the WT allele was assigned by aligning the sequences from 
our population groups to the CCL4 sequence of P. troglodytes. The ancestral allele (G) was thus 
regarded as the WT, and was interestingly more prevalent in the Caucasian population.  The reported 
frequency of the A allele in the 1000 Genomes Project database, in the combined European 
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populations, is 30%, which is higher than the frequency observed in Caucasian individuals in this study 
(20%), while in the Yoruba population, a Sub-Saharan population which is most likely to be more 
genetically similar to the South African Black population than any other 1000 Genomes populations, 
this polymorphism occurred at a frequency of 31% (Abecasis et al. 2012) while it was observed at a 
frequency of 46% in black individuals in this study.  The majority of SNPs were located in intronic and 
promoter regions, while the exons and UTRs were not rich in SNPs (Table 3.5.1). Exonic polymorphisms 
within the Black population included two SNPs in exon 1, a single SNP in exon 2 and two SNPs in exon 
3. In Caucasian individuals, one SNP in exon 1 and two SNPs in exon 3 were identified. The two SNPs 
in exon 3 were common between the two populations.  Only one SNP detected was not previously 
reported (position: -1063) and was identified in the Black population in the region upstream from the 
CCL4 promoter region.  
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Table 3.5.1 SNPs and indels identified in the South African Black and Caucasian populations 
 
Figure 3.5.1 (A) Schematic representation of the CCL4 gene. (B) Venn diagram indicating the percentage of SNPs 
identified for the Black (black area) and Caucasian (white area) population groups and the percentage of SNPs 
that are shared by both race groups (grey area) 
dbSNP Acession Number Position Base Change (wt/mt)
Black Caucasian
n=23 n=32
rs143457996 -1095 G/A 4,35 -
newly identified -1063 C/G 2,17 -
rs540786592 -973 C/T - 1,56
rs1160085153 -953 C/T 6,52 -
rs140335931 -914 C/G - 4,69
rs10491121 -884 G/A - 34,38
rs145502799 -832 C/T 6,52 -
rs1719140 -807 A/T 17,39 -
Promoter rs1719141 -770 G/T 10,87 28,13
rs9895259 -764 G/C 6,52 -
rs79409766 -706 T/C 15,22 -
rs79409767 -678 C/G 10,87 28,13
rs113682499 -665 G/A 2,17 -
rs143637961 -625 G/A 4,35 -
rs113245686 -603 INDEL -/T 6,52 -
rs139348900 -534 INDEL -/C 6,52 -
rs9895812 -502 G/C 6,52 -
rs9896211 -392 G/A 15,22 6,25
rs62079738 -319 G/A - 3,13
rs1634514 -302 T/A 10,87 28,13
rs555131559 -274 T/C 2,17 -
rs191820992 -177 A/G 6,52 -
rs577987679 -164 G/C 2,17 -
rs143208576 -97 G/A 2,17 -
rs1049746 -9 G/C 10,87 28,125
rs147511844 -1 C/T 2,17 -
5' UTR rs1049750 68 T/G 17,39 -
Exon 1 rs149488954 94 G/C 2,17 -
rs143966312 141 C/T - 1,56
rs150142971 155 A/G 4,35 -
Intron 1 rs138567234 156 G/A 8,70 -
rs1719144 184 G/A 4,35 31,25
rs4606761 216 G/T 6,52 -
rs7218357 367 C/T 6,52 -
rs116657123 633 G/A 45,65 20,31
rs55906345 665 C/T 13,04 -
rs184395846 666 G/A 6,52 -
Exon 2 rs1719146 742 C/T 13,04 -
Intron 2 rs541137737 834 INDEL -/G 2,17 -
rs2905542 870 A/T 2,17 -
rs150004330 875 A/G 2,17 -
rs1719147 906 G/A 36,96 20,31
rs72833526 1018 G/A - 48,44
rs1634516 1023 G/C 10,87 28,13
rs1719148 1078 A/G 19,57 28,13
rs1634517 1184 C/A 23,91 31,25
rs9891632 1279 T/C 8,70 -
rs1719149 1362 T/C 2,17 28,13
rs1719150 1367 A/G 2,17 28,13
Exon 3 rs1049807 1444 A/G 15,22 28,13
rs1719152 1445 T/A 10,87 29,69
rs184099447 1653 T/C 2,17 -
3' UTR rs1049833 1704 G/C 8,70 -
rs148133700 1725 C/T - 4,69
rs1634518 1810 A/G - 26,56
rs1719153 2010 A/T 10,87 28,13
rs113909899 2063 C/T 4,35 -
rs146185601 2164 C/G 8,70 4,69
rs3216921 2197 INDEL: -TAT - 14,06
rs139373922 2319 C/T 2,17 -
rs187291062 2489 C/A - 3,13
rs1634519 2615 G/A 10,87 28,13
rs28547364 2709 G/A 17,39 6,25
rs2522126 2720 C/G 4,35 28,13
rs2687507 2745 C/T 10,87 29,69
rs12939657 2758 G/A 10,87 -
rs142188747 2776 G/A 2,17 -
rs113485141 2836 G/A 2,17 -
rs9892580 2892 T/C 23,91 -
rs142438706 2937 T/C 2,17 -
rs116923441 2962 C/G - 3,13
rs17679451 3099 G/A 4,35 4,69
rs373596785 3309 T/G 2,17 -
rs76690362 3316 G/A 4,35 4,69
rs62079742 3326 T/C - 14,06
rs141572011 3364 G/A 4,35 4,69
rs145428208 3423 T/A 2,17 -
rs1619526 3426 C/T 13,04 28,13
rs1619600 3456 A/G 6,52 26,56
rs17617372 3480 G/A 2,17 4,69
Minor Allele Frequency (%)
3’ UTR
1
Exon 2
Exon 3
Exon 1
5’ UTR
79bp
76bp
547bp
114bp
87bp
309bp
583bp
A
B
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3.5.2. Influence of exonic SNPs on protein translation 
Of the total, six SNPs were identified in exons, three of which, were non-synonymous mutations 
(rs143966312, rs150142971, rs1719152).  The resulting amino acid changes from these 
polymorphisms in the protein coding region are: Ala21Val, Met26Val and Ser80Thr (Figure 3.5.2, 
amino acid codes are listed in Appendix C). In order to, putatively predict possible conformational and 
therefore functional implications of these amino acid changes to the CCL4 protein, the three 
substitutions were run through the Poly-Phen 2-prediction of functional effects of human nsSNPs data 
base (Adzhubei et al. 2010).  The Ala21Val, Met26Val and the Ser80Thr amino acid substitutions were 
predicted to be ‘benign’, i.e. not affecting protein stability and function, with scores of 0.002, 0.000 
and 0.000 respectively on a scale that ranges from 0 to 1. None of the exonic SNPs occurred within 
the codons for the conserved cysteine residues or amino acids involved in binding (amino acids which 
form part of the conserved CC chemokine family structure are indicated by amino acids underlined in 
grey in Figure 3.5.2). The Ala21Val substitution does occur in the signal peptide binding site (indicated 
by amino acids in a black box in Figure 3.5.2) and the SNP was only identified in a single individual in 
the Caucasian cohort (Table 3.5.1; allelic frequency 1.56%). 
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Figure 3.5.2 Influence of CCL4 exonic SNPs on CCL4 amino acid sequence. Lines of sequence are followed by 
the corresponding amino acid sequence, the ‘.’ representing a stop codon.  A dotted line under the respective 
sequences indicated homology and lack thereof is indicated by the base substitution at the specific site.  Shading 
behind amino acid sequences denote the exon from which that particular sequence was transcribed, that is, 
purple shading: exon1, green shading: exon 2, orange shading: exon 3. The first few bases enclosed in a box 
represent the CCL4 signal peptide. Amino acids underlined in grey are involved in binding and the conserved 
cysteine residues are underlined in red. 
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3.5.3. Insertions/Deletions 
Four indels were identified when sequence data was analysed: rs113245686, rs139348900, 
rs541137737, rs3216921 at positions -603, -534, 834 and 2197 respectively (Table 3.5.1). Three of the 
four indels were identified in Black individuals only, one of which only occurred in a single individual.  
All the indels, which were reported as deletions, had been previously described in dbSNP.  
 
The indel at position 2197 was in a region of AT repeats which meant that determining which bases 
were deleted was difficult as the repetitive nature of the region would influence sequence alignment. 
Even within dbSNP, there are multiple reports of a deletion in this area, overlapping by a few bases 
and, while most reports agree that it is a 3bp deletion, the exact nucleotide sequence of the deleted 
portion is unclear.  One such alternate identifier for the rs3216921 deletion is rs147387560 and 
population data for this SNP available from the 1000 Genomes Project (Abecasis et al. 2012) suggests 
that in the Yoruba population, this deletion occurs at a frequency of 2%. The South African Black 
individuals in this study did not have this deletion at all. In European populations (1000 Genomes 
Project), the recorded frequency of this indel is 44%, which is strikingly lower than the 14% prevalence 
which was identified in South African Caucasian individuals.  
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Figure 3.5.3 Schematic representation of putative CCL4 haplotypes identified in the South African Black and Caucasian populations.  All CCL4-SA-HapB patterns were 
identified in Black individuals while all CCL4-SA-HapC patterns were identified in the Caucasian cohort. The haplotype CCL4-SA-Hap1 was identified in both populations.  SNP 
positions, SNP identification numbers, base changes as well as position relative to the various gene elements are indicated in the figure and the adjacent list. Haplotype 
frequencies in the Black and Caucasian population are represented.
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3.5.4. Putative haplotypic structure of CCL4 and flanking regions 
Upon visual examination of the SNP/indel data across the CCL4 gene region in both populations, we 
observed distinct patterns between various variations which were defined as putative haplotypes.  
Four putative haplotypes were identified in the Caucasian population and three haplotypes were 
identified in the Black population (Figure 3.5.3). Only a single haplotype (CCL4-SA-1) was shared 
between the Black and Caucasian population (Figure 3.5.3). Primer positioning for CCL4 meant that a 
very large fragment had to be amplified, which contained large upstream and downstream regions. 
SNP data for these regions have thus been included and we identified that haplotypes extended into 
these highly polymorphic regions.  
 
Due to the large number of polymorphic loci in Black individuals, it was difficult to putatively assign 
haplotypes.  Analysis of the Black population SNP/indel data using Haploview software shown in Figure 
3.5.4, shows very few blocks of linked variants, indicated by red squares. The pattern observed in the 
Caucasian population, however, (Figure 3.5.5) is very different with large regions of LD.  Figure 3.5.6 
represents the SNPs predicted to form haplotypes CCL4-SA-HapB1 (A), CCL4-SA-HapB2 (B) and CCL4-
SA-HapB3 (C).  Some SNPs that were predicted to form part of these haplotypes showed partial linkage 
to the other SNPs in the haplotype. Haplotype frequencies in the Black population were calculated by 
including individuals that had all the SNPs of a given haplotype. Haplotypes occurred at frequencies 
ranging from 4-34% (Figure 3.5.3). 
 
CCL4-SA-HapC1 is a large haplotype consisting of 11 SNP loci, the majority of which are located in the 
second intronic region of CCL4.  Of the total six SNPs that were located in exons, two of these are 
found in this haplotype, i.e. the two SNPs that lie adjacent to each other at positions 1444 and 1445 
(Table 3.5.1; rs1049807 and rs1719152). Interestingly, rs1719152 is one of the three non-synonymous 
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SNPs identified, leading to the Ser80Thr change (Figure 3.5.2).  CCL4-SA-HapC1 occurred at a genotypic 
frequency of 28.13% and of the 13 individuals with this haplotype, five individuals were homozygous 
for all SNPs in the haplotype which may suggest that linkage disequilibrium between the SNPs is 
complete, however upon Haploview analysis, it became apparent that SNP rs1635417 at position 
1184, showed incomplete linkage with the other SNPs in the haplotype as this was a very prominent 
SNP, occurring at an allelic frequency of 31.25% in the Caucasian population, suggesting that this SNP 
will always occur as part of this haplotype but may occur independently of the haplotype as well. 
 
Haplotypes CCL4-SA-HapC2 and CCL4-SA-HapC3 are both haplotypes comprised of two SNPs and were 
both very prevalent, observed in 34.38% and 20.31% of the Caucasian cohort respectively (Figure 
3.5.3).  Like CCL4-SA-HapC1, when individuals with the CCL4-SA-HapC3 haplotype were homozygous 
for one of the SNPs, they were also homozygous for the other, implying complete linkage 
disequilibrium between the two SNPs.  This, however was not observed for CCL4-SA-HapC2, which 
was the haplotype that was present in over half of the Caucasian individuals (Figure 3.5.3; 34.38%). 
Haploview analysis indicated that the SNP rs72833526 (position 1018), which occurred at a frequency 
of 48.44% in the Caucasian population, was incompletely linked with the SNP rs10491121 (position -
884) with an r2 value of 0.55 (Figure 3.5.5) The SNPs making up CCL4-SA-HapC3, rs116657123 (position 
663) and rs1719147 (position 906) are also very prevalent in the Black cohort with allele frequencies 
of 45.65% and 39.69 % respectively (Table 3.5.1).  A three-SNP haplotype, CCL4-SA-HapC4, displayed 
complete linkage between the SNPs rs140335931 (position -914), rs148133700 (position 1725) and 
rs146185601 (position 2164).   
 
 One three-SNP haplotype, CCL4-SA-HapB1 and two seven SNP haplotypes, CCL4-SA-HapB2 and CCL4-
SA-HapB3, were identified in the Black population, occurring at genotypic frequencies of 10.87%, 
8.70% and 6.52% respectively (Figure 3.5.3). The exon two SNP at position 742 (rs1719146; Table 
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3.5.1) forms part of CCL4-SA-HapB1 and the SNP at position 1445 (rs1719152; Table 3.5.1), which is a 
non-synonymous SNP in exon 3 forms part of the CCL4-SA-HapB2 haplotypes, as reported above, this 
SNP also forms part of the CCL4-SA-HapC1 Caucasian haplotype.  While three of the four haplotypes 
identified in the Caucasian population had frequencies> 20%, the haplotypes in Black individuals were 
far less frequent, i.e., none of the three haplotypes identified had a frequency>20%, which was 
expected from the patterns of linkage seen in Figures 3.5.4 and 3.5.5. Some SNP loci making up the 
haplotypes CCL4-SA-HapB1, CCL4-SA-HapB2 and CCL4-SA-HapB3 overlapped with those that formed 
part of haplotypes in the Caucasian population (positions: -302, 1023, 1445, 2010; Figure 3.5.3).  
 
A four-SNP haplotype, CCL4-SA-Hap1, was identified in the region downstream from the CCL4 3’UTR 
region, in both Black and Caucasian individuals (Figure 3.5.3). It was however not a very prevalent 
haplotype, occurring in only two Black and three Caucasian individuals, that is, with minor allele 
frequencies <5%.  
3.5.5.Hardy-Weinberg Equilibrium 
All SNP positions in both the Black and Caucasian cohorts did not deviate from Hardy-Weinberg 
equilibrium, except for the SNP at position 1018 in the Caucasian population (rs72833526; Table 
3.5.1).   There is a G/A change at this position and the majority of Caucasian individuals were 
homozygous for the A allele.  This SNP was absent in the Black population group. It is interesting to 
speculate whether this intronic SNP has been the focus of selective pressure and may thus play a role 
in splicing.  
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Figure 3.5.4  Pairwise LD among SNPs (>5% prevalence) across the CCL4 gene in South African Black individuals. The significance of association (r2) between SNP pair-wise 
LD values are given in each diamond. A deep red block represents maximum r2 values and LD of 1. Relative positions of SNPs on the CCL4 gene are shown. 
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Figure 3.5.5 Pairwise LD among SNPs (>5% prevalence) across the CCL4 gene in South African Caucasian individuals. The significance of association (r2) between SNP pair-
wise LD values are given in each diamond. A deep red block represents maximum r2 values and LD of 1. Relative positions of SNPs on the CCL4 gene are shown. 
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Figure 3.5.6 Pairwise LD among SNPs (>5% prevalence) across the predicted CCL4 haplotypes in South African Black individuals. CCL4-SA-HapB1 (A), CCL4-SA-HapB2 (B) 
and CCL4-SA-HapB3 (C) are represented. The significance of association (r2) between SNP pair-wise LD values are given in each diamond. A deep red block represents 
maximum r2 values and LD of 1. Relative positions of SNPs on the CCL4 gene in the two populations are shown. 
A B C
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3.5.6. The influence of Genetic Variation on CCL4 production  
The influence of various prevalent SNP and haplotype combinations to CCL4 protein production was 
investigated. No association between these genetic factors and CCL4 production were observed.  
Some comparisons of interesting variants were limited by sample size as the small number of 
individuals possessing the variant would not allow for valid statistical comparisons.  
 
Three of the four indels that were identified were too infrequent to have any influence on production. 
The comparison of levels of CCL4 production in Caucasian individuals who had the deletion at position 
2197 (rs3216921; Table 3.5.1) and those who did not, revealed that individuals with the deletion had 
a significantly higher level of PHA-stimulated CCL4 production but not unstimulated production, than 
those that did not possess the deletion (p=0.024; Figure 3.5.7). Due to the discrepancy with the actual 
bases that have been deleted in this region (section 3.5.3), the Figure 3.5.7 X-axis is simply labelled as 
‘deletion’ and ‘no deletion.’ 
 
This deletion is found downstream from the 3’UTR. It is interesting to speculate as to how flanking 
region variants may impact on transcription or if these variants are somehow involved in miRNA 
binding.  
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Figure 3.5.7 Comparison of CCL4 production in Caucasian individuals with and without the rs3216921 deletion 
in the CCL4 gene 
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CHAPTER 4 DISCUSSION AND CONCLUSIONS 
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Approximately 12% of the human genome displays CNV and the functional significance of these 
variations fall within a wide range. Many studies have provided examples in which gene copy number 
variability can influence disease outcomes (Freeman et al. 2006; Redon et al. 2006; Wain et al. 2009). 
The downfalls of the methods, such as qPCR to accurately determine CNV, particularly at higher copy 
numbers, have been partly accountable for the controversy questioning whether associations 
generated from these methods can be considered true as they are not always reproducible (Shrestha 
et al. 2009; Cantsilieris and White 2013). These contradictions have had a significant influence in 
determining the link between copy number of the CC chemokine encoding genes and protection 
against HIV-1 infection and disease attenuation.  
 
A number of studies have demonstrated the accuracy of ddPCR for a variety of applications including 
copy number determination of the CCL3 encoding genes (Hindson et al. 2011; Heredia et al. 2013).  In 
this study, the comparison of qPCR and ddPCR to determine gene copy number of CCL4L, CCL4L1 and 
CCL4L2 genes in South African Black and Caucasian populations clearly demonstrated the differences 
in accuracy of these two methods.  
 
Genotyping of the CCL4 encoding genes is ideal for comparing CNV assays because copy number of 
the CCL4L1 and CCL4L2 genes can be determined individually and together as CCL4L. The sum of the 
number of copies of CCL4L1 and CCL4L2 should therefore equal to the copy number generated for 
CCL4L (Shostakovich-Koretskaya et al. 2009), and the relationship between these values gives a good 
indication of the accuracy of an assay.  Although, the correlation of these two factors maintained 
significance when assessed by qPCR (r=0.87) there was a stronger correlation observed when ddPCR 
(r= 0.99) was performed. Furthermore when one looks at the correlations below and above a CCL4L 
copy number of 3, the qPCR assay shows a very weak correlation (r=0.44) at CCL4L copy numbers >3, 
whereas the ddPCR assay is almost 100% correlated (r=0.99).The number of individuals in whom the 
The Role of CCL4 in HIV infection» Discussion and Conclusions 
 
 
 
 
84 
 
two values did not correspond was thus far greater when qPCR was used compared to the ddPCR 
assay, where just three incidences were observed.  Two of the three unusual patterns observed in 
ddPCR were explained by SNPs in the probe binding sequence and at the 3’ end of a reverse primer, 
which were detected by sequencing the CCL4L genes of the three individuals. It is suspected that the 
third unusual pattern observed, is perhaps a result of SNPs within the BGB gene which would result in 
an incorrect gene copy number but would still maintain a correct gene ratio. The presence of both the 
CCL4L1 and CCL4L2 genes in the third individual was confirmed by standard amplification and 
sequencing of these genes.  Interestingly, although the copy number patterns of the individuals 
generated by ddPCR were seen in some of the repeats when raw qPCR data was examined, the 
inconsistency of the results lead to a final determination of 0 copies of the CCL4L genes in these 
individuals. In contrast, the same patterns were consistently observed between replicates within an 
experiment and upon repetition of the experiment with ddPCR. The consistency of these results 
impelled the further investigation by sequencing and the findings highlight the sensitivity and accuracy 
of the ddPCR assay.       
 
Concurring with previous reports (Gonzalez et al. 2005; Picton et al. 2013), the qPCR assay had reduced 
accuracy at higher gene copy numbers. This is particularly disadvantageous in a South African context 
as African populations have previously been reported (Colobran et al. 2008), and corroborated in this 
study, to have higher CCL4L copy number medians and ranges. While the highest copy number of the 
CCL4 encoding genes did not exceed 6 copies, many genes that display CNV have much higher copy 
number ranges. The CCL3 encoding genes, for example, have been found to occur in up to 20 copies 
pdg (Gonzalez et al. 2005). Similar to CCL4L, the CCL3L1 genes were shown to occur in higher copies 
in African populations. Furthermore this gene has been found to occur in even higher copies in 
chimpanzees with a mean copy number of 9 (Gonzalez et al. 2005). Application of the ddPCR assay 
could thus also be greatly beneficial to CNV studies being conducted in non-human primates. 
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 The development of the paralogue ratio test (PRT) for CCL3L copy number determination and its 
subsequent application suggests that the duplicated region on chromosome 17, in which the CCL3L 
and CCL4L genes fall, will always contain the same copy number of CCL3L and CCL4L (Walker et al. 
2009; Carpenter et al. 2012; Carpenter et al. 2014). However, applying this method in some African 
population studies and using FISH to verify results suggested that heterogeneity may exist in this 
region, unlike in European populations (Aklillu et al. 2013). Cardone et al. (2008) suggest that break 
points within this duplicated region would allow for the copy number of the CCL3L and CCL4L genes 
to vary from one another. Interestingly, when comparing the copy number data generated for CCL4L 
with that generated for CCL3L in the same cohort (Picton et al. 2013), a positive strong correlation is 
seen in both population groups, but as observed by Shostakovich-Koretskaya et al. (2009), the CCL3L 
copy numbers are higher than CCL4L. While Walker et al. (2009) suggest that the difference observed 
in copy number when CCL3L and CCL4L are compared is a result of the failure of studies to exclude the 
CCL3L2 gene (i.e. truncated gene), a significant positive correlation is maintained when excluding 
CCL3L2 (data not shown), however copy numbers were still not equal. In order to further elucidate 
the relationship of CCL3L and CCL4L in sub-Saharan African populations, determining both CCL3L and 
CCL4L copy number using ddPCR in the same cohort will be highly informative and is planned for future 
studies. Furthermore, as ddPCR becomes more widely implemented over time, it will be interesting to 
see how the PRT test performs relative to ddPCR using the same dataset or cohort.  
          
Inaccuracy of qPCR at higher copy numbers was evident when population ranges and medians were 
examined. While both assays produced the same copy number medians for all three genes for the 
Caucasian population, calculated medians differed between the two methods for the African 
population.  The copy number distribution around the population medians appeared to follow a very 
similar pattern when results from both assays were compared for the Caucasian population. This was 
not observed in the Black population. CCL3 and CCL4 are the natural ligands of the CCR5 receptor, 
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which is a major co-receptor, used by HIV-1 to infect cells, and have been studied extensively for their 
role in HIV disease (Cocchi et al. 1995). Incorrectly establishing median copy number has implications 
for association studies that aim to determine the relationship between CNV, protein production and 
their impact on various communicable and non-communicable diseases. Having higher copy numbers 
of some of the CCL3 and CCL4 encoding genes, more specifically ,above the population specific 
median, has been shown in several studies to influence protein production and to have protective 
effects against HIV-1 transmission (Gonzalez et al. 2005; Meddows-Taylor et al. 2006; Kuhn et al. 2007; 
Shostakovich-Koretskaya et al. 2009).  The protective effects of CCL3 have also been demonstrated in 
mother to child transmission studies (Meddows-Taylor et al. 2006; Kuhn et al. 2007).  
 
Although the set-up of a ddPCR experiment involves several more steps than qPCR, that is, restriction 
digestion, droplet generation, a conventional PCR and then the result-generating droplet reading step,  
and is consequently more time consuming than qPCR, only three of the samples needed to be 
repeated. In contrast, the results generated using qPCR showed differences between repeats for a 
single sample both within and between experiments. On average, samples assayed using qPCR had to 
be repeated three times and two samples remained unresolved. Average copy number values 
calculated from ddPCR replicates clustered close to whole integers, minimizing ambiguity.  Data 
generated by the qPCR assay did not display the same type of clustering and samples were often 
repeated when it was unclear if the copy number was the integer above or below the average value 
calculated.   
 
A minor drawback of ddPCR is that a larger quantity of DNA had to be used compared to qPCR. The 
amount of DNA required still remained higher than qPCR even when all the qPCR repeats were 
considered. This may be a disadvantage when conducting studies in which limited DNA is available. 
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Since the technology is relatively new, as its popularity and implementation grows, we envisage that 
the limitations of the assay will be improved upon. 
 
In the evaluation of gene copy number, absolute quantification, as in ddPCR, rather than the 
extrapolation of data from a standard curve, as in qPCR, seems to be far more advantageous. In qPCR, 
the amplification efficiencies of the endogenous control and the genes of interest have to be the same 
as data is generated as a ratio of the quantities generated from the two reactions. While for ddPCR, 
the data generated is independent of the PCR efficiency as it is generated using the number of end-
point positive reactions (Hindson et al. 2011). The experimental design is therefore far simpler and 
requires less optimization.   
 
While our interests lie in determining the role of the CCL3 and CCL4 encoding genes in HIV-1 infection, 
there are several other disease studies to which this modified CCL4L assay can be applied. CCL4 has 
been implicated in susceptibility to tuberculosis and leprosy (Jamieson et al. 2004), severity of 
psoriasis (Pedrosa et al. 2011) and dengue fever (Bozza et al. 2008).  The advantages of using ddPCR 
over qPCR when assaying high CNV have already been discussed in this study.  Other studies have also 
benefited from the increased sensitivity of ddPCR and other forms of digital PCR over qPCR, for 
example, the detection of rare targets such as HER2 tumour gene copies from cell free DNA of breast 
cancer patients which is diluted by normal DNA  (Whale et al. 2012).  Droplet digital PCR was also 
shown to be more effective than using methods such as FISH and immunohistochemistry for HER2 
detection (Heredia et al. 2013).  The technology has also been used to detect and quantify HIV-1 
proviral DNA in HIV-1-infected patients (Strain et al. 2013).   
 
This study also aimed  (i) to investigate the influence of CCL4L CNV, generated by ddPCR,  on CCL4 
production, in a cohort of HIV-1-uninfected individuals, (ii) to compare these findings to the closely 
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associated CCL3 chemokine data generated by Picton et al. (2013 and unpublished data), and (iii) to 
carry out a preliminary investigation of the role of CCL4 in HIV-1 control by looking at a small subset 
of LTNPs with respect to CCL4 copy number and production compared to HIV-uninfected individuals 
from the same population demographic.   
 
As previously described above and further expanded upon now, the Black South African population 
displays a wider range of copy number variability, higher median copy numbers as well as a greater 
diversity of copy number combinations of the genes CCL4L1 and CCL4L2, than the Caucasian 
population. Although Black females showed significantly higher CCL4L copy numbers than Black males, 
the addition of copy number data from a cohort of 30 females to the cohort may have skewed the 
results due to the large difference in the number of Black females compared to Black male 
participants, however future studies involving larger matched groups would need to be carried out to 
determine if this is a true association and what this could mean about the evolution of these genes.   
 
The negative correlation between CCL4L1 and CCL4L2 gene copy number and the reported 
(Shostakovich-Koretskaya et al. 2009) opposing effects of these genes in HIV-1 infection is an intriguing 
phenomenon, especially since other similar gene correlations in this study were positive, including 
when the genes CCL3La and CCL3Lb were compared, and these genes too give rise to a functional CCL3 
protein and a truncated protein, respectively (Shostakovich-Koretskaya et al. 2009). Since CCL4L1 
encodes a protein with CCL4 functionality, and the splice variants of CCL4L2 do not seem to give rise 
to proteins that have ‘classical’ CCL4 functionality (Colobran et al. 2005), it is interesting to speculate 
whether the ‘non-functional’ CCL4L2 gene has a post-transcriptional positive regulatory effect on CCL4 
production (i.e. increases CCL4 production), and that levels of CCL4 production have been 
evolutionarily controlled/maintained by the inverse copy number relationship of these two genes. 
Regarding the relationship between CCL3-encoding genes and CCL4-encoding genes, Shao et al. (2007) 
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reported a positive correlation between the CCL3L and CCL4L genes, however, both Shao et al. (2007) 
and Shostakovich-Korestskaya et al. (2009) determined that the these gene copy numbers were not 
identical. Comparing CCL4L and CCL3L (Picton et al. 2013) copy number data in the Black and Caucasian 
cohorts in this study also a showed significantly positive correlation, except however when CCL3Lb 
and CCL4L2 were compared in the Black population. Furthermore, the copy number of CCL3La was 
significantly higher than CCL4L1 copy number in the Black but not in the Caucasian population. These 
population variations in copy number distribution were overlooked during the design of the paralogue 
ratio test for CCL3L and CCL4L copy number determination (Walker et al. 2009). 
  
When assessing CCL4 protein production by ELISA, it is assumed, as has been indicated for CCL3, that 
the assay cannot distinguish between the contribution of protein from the CCL4 gene, which occurs at 
two copies pdg, and CCL4L1, since the protein sequences of these genes differ by only a single amino 
acid. None of the CCL4L genes, individually or combined, correlated with protein production in either 
Black or Caucasian individuals. Making the broad assumption that the contribution from CCL4 is 
constant, the correlation between gene copy number of the CCL4L encoding genes and CCL4 
production was examined by dividing CCL4 production by gene copy number (i.e. comparing CCL4 
production per CCL4-encoding gene copy). Although Caucasians had significantly higher CCL4 
production per CCL4L copy number compared to Black individuals, this was not maintained when 
looking at CCL4L1 (or CCL4L2) alone or when we corrected for the effect of CCL4L copy number ((i.e. 
compared individuals from two populations with similar CCL4L copy number (and distributions of 
CCL4L1 and CCL4L2)). Several studies have suggested that the protective effects of CCL3L and/or CCL4L 
on HIV-1 did not show with the exact copy numbers per se, but rather when looking at copy numbers 
relative to the population mean. We therefore stratified CCL4 production based on the population 
medians generated for the Black and Caucasian populations. Similar to the pattern (albeit not 
significant) that was observed between CCL3 production and CCL3La copy number (Picton et al, 2013), 
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we observed a significantly lower level of CCL4 production by Black individuals with CCL4L copy 
number below the population median compared to production by individuals with median CCL4L copy 
number. This association however was not maintained when CCL4L1 and CCL4L2 were analysed 
individually in the same manner. Furthermore the inverse relationship was observed (i.e. median 
production by median copy number was lower than production of lower copy number individuals, 
although lacking significance). The negative correlation seen between CCL4L1 and CCL4L2 may be a 
possible explanation for the latter observation. The significant lower production seen at CCL4L copy 
number below the population median may indeed be reflective of the lower copy number, i.e. copies 
below the median all translate into protein. At the median, it seems that production is optimal, 
however copy number above the median does not seem to translate into an expected higher 
production, suggesting that at the higher copy number, post-transcriptional regulation may be 
“kicking” in to keep the production at an optimum threshold. It has to be kept in mind that while the 
‘pseudogene’ of CCL3L produces a truncated protein, the case of CCL4 may be more complex because 
the most abundant CCL4L1 transcript has been shown to produce a protein that is missing the first 5 
amino acids of exon 3 which may prevent it from forming heterodimers and self-aggregates (Colobran 
et al. 2005). Since it is not known which epitopes the antibody in the ELISA system binds to, it cannot 
be totally ruled out that protein products from these spliced variants are being detected.  
 
What is most notable when comparing the scenarios of CCL3L and CCL4L, is that in the case of CCL3L, 
associations mostly relate to CCL3La gene copy number (which includes the genes CCL3L1 and CCL3L3, 
both producing a functional CCL3 protein) but in the case of CCL4, they are formed around CCL4L gene 
copy number (the combination of CCL4L1 and CCL4L2). Comparing CCL4 copy number and production 
data to CCL3 data generated by Picton et al. (2013) in the same two cohorts, revealed a positive 
significant correlation of CCL3 and CCL4 protein levels in the Caucasian but not the Black population. 
However, CCL4 protein levels were higher than that of CCL3 in both populations. 
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Picton et al.’s (2013) study of the distribution of the CCL3L genes as well as their association with CCL3 
protein production  did not find marked differences in both stimulated and unstimulated production 
of CCL3 and neither did this study on CCL4, respectively, between the two population groups.  An 
association between CCL4L and CCL4 production was not observed in a cohort of Black LTNPs in this 
study either, similarly, nor was there a correlation between CCL3 and CCL3L production in the same 
cohort of Black LTNPs (Picton et al., unpublished). We have however observed that LTNP individuals 
have lower levels of both CCL3 and CCL4 protein production compared to uninfected individuals. 
Examining chemokine production within the LTNP cohort of Black individuals alone, it was discovered 
that those individuals with viral loads less than 400 RNA copies/ml had lower levels of CCL4 in both 
unstimulated and PHA-stimulated PBMC supernatants than those with viral loads greater than 400 
RNA copies/ml.  The same was seen for PHA-stimulated CCL3 production in the same cohort (Picton 
et al, unpublished). Furthermore the LTNPs with viral loads less than 400 RNA copies/ml produced 
significantly less unstimulated and PHA-stimulated CCL4 compared to the uninfected individuals. 
Although these findings may be influenced by the small size of the LTNP cohort, these interesting 
results warrant further investigation, using larger cohorts of HIV-1 controllers and investigating 
whether these associations are uniquely seen in CCL3 and CCL4 or whether other chemokine 
production is similarly dampened and what this means in terms of the ability of these unique 
individuals to control HIV-1 infection. Given that these chemokines are involved in immune feedback 
mechanisms, lower level of production in LTNPs may lead to a less active immune response to HIV-1 
infection. It would also be interesting to compare whether or not HIV-1 progressors display an 
opposite phenotype, that is, do they produce higher levels of CCL3 and CCL4 compared to uninfected 
individuals and LTNPs. 
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The examination of a cohort of Caucasian LTNP individuals showed that they had a higher frequency 
of the CCR5Δ32 heterozygotes individuals compared to progressors and rapid progressors, (Stewart 
et al. 1997). This point reiterates the need to conduct population specific studies on these LTNP 
individuals because the majority of the LTNP individuals in our study are Black and this mutation is not 
prevalent in the Black population suggesting that there are perhaps a number of independent factors 
that can influence disease progression.  While some studies are uncertain if chemokines contribute to 
slow progression (Gea-Banacloche et al. 2000), others suggest that perhaps studying chemokine 
production in areas such as the lymph nodes may reveal different results from studies that focus on 
the level of circulating chemokines in the blood (Pantaleo et al. 1995). 
 
Since the contribution of the two copy pdg gene CCL4, to CCL4 production has not been accounted for 
when looking at copy number, we carried out a preliminary characterisation of the genetic variants 
found in this gene in the two population groups and analysed these variants with respect to their 
influence on CCL4 production.  We identified a total of 22 SNPs within the CCL4 gene in the Black South 
African cohort and 12 SNPs in Caucasian individuals. Several other SNPs upstream and downstream 
from the gene were also identified.  Just a single SNP, occurring in one Black individual, was newly 
identified in this study.  In the same population, genetic characterization of CCL3 yielded 25 intragenic 
SNPs being identified in Black individuals and 9 SNPs in Caucasian individuals (Paximadis et al. 2009). 
Five CCL3 SNPs were newly identified. We have described four novel haplotypes in the South African 
Caucasian population, three in the Black population, and a haplotype that is shared between both 
population groups. To our knowledge, the only other study to have described LD and haplotype 
structure incorporating the CCL4 gene was done by Modi et al. (2006), only four SNPs that were 
incorporated in their study overlapped with the SNPs identified in our study (rs1634514, rs1719144, 
rs1719146, rs1719153). The SNPs rs1634514 and rs17179153 (D’ =98, Modi et al. 2006) were 100% 
linked in both our population groups. Our study is first to have comprehensively reported the LD 
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pattern across this gene for both Black and Caucasian South African individuals. Again, compared to 
CCL3, three haplotypes were identified in the Black cohort while only one haplotype was characterised 
in the Caucasian population group (Paximadis et al. 2009).  Generally, Caucasian populations tend to 
exhibit greater linkage disequilibrium owing to less genetic diversity and ‘less time’ for genetic 
recombination events to occur (Reich et al. 2001). 
 
The majority of CCL4 SNPs that were identified in both populations were positioned from the second 
intron onwards while the area before the second intron is rich in SNPs that are unique to the Black 
cohort. This can also be seen when examining the haplotypes that were predicted for each population 
group. The only shared haplotype, CCL4-SA-Hap1, harboured four SNPS downstream from the gene. 
Out of the four Caucasian haplotypes identified, in the one that was most prevalent, CCL4-SA-HapC1, 
the majority of SNPs fell within the second intron. The only SNP that deviated from Hardy-Weinberg 
equilibrium, rs72833526 (position 1018), which seems to have been selected for in Caucasians, but is 
not present in Black individuals in this cohort, is also situated in the second intron. This is interesting 
given that the genes CCL4L1 and CCL4L2 differ by a single SNP in the acceptor splice site in intron 2, 
resulting in aberrant splicing of many products that do not seem to have any chemokine activity. The 
ancestral chimpanzee sequence is often used as a reference in assigning human WT alleles when they 
are unclear.  Chimpanzees however, do not have the CCL4L2 and CCL3L2 genes, which are both 
considered the ‘non-functional,’ non-allelic isoforms of CCL4 and CCL3 respectively. Furthermore, we 
found that these genes also occur in multiple copy numbers and in the case of CCL4, the CCL4L2 genes 
occur at a higher copy number than CCL4L1. It has been suggested that a much higher genetic diversity 
is present in the human CCR5 gene compared to the CCR5 gene in chimpanzees and that in some 
cases, the predominance of certain SNPs in humans meant that they had lost certain conserved 
mRNAs found in other apes but had gained the ability to form novel mRNA sequences (Mummidi et 
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al. 2000). It is a possibility that the same response to evolutionary pressure, perhaps driven by select 
immunological events, which is seen in CCR5, is also impacting the genes encoding its ligands. 
   
Three out of six exonic SNPs identified were non-synonymous, however, the amino acid changes that 
resulted were predicted to be ‘benign’ in terms of the way that they may impact protein function. It 
has been suggested that certain synonymous codons may be selected for, due to their association 
with exonic splicing regulatory elements  (Parmley and Hurst 2007). Both the synonymous SNP 
rs1049807 at position 1444 and its neighbour at position 1445, the non-synonymous rs1719152, form 
part of the most common Caucasian haplotype that we identified (CCL4-SA-HapC1).  
 
Two of the SNPs found in this study rs1719146 (C742T) and rs1719153 (A2010T) were found to be 
associated with an increased progression to AIDS in Black and Caucasian individuals respectively (Modi 
et al. 2006).  This association was observed in individuals who were both homozygous or heterozygous 
for the polymorphisms. While the minor allelic frequency for rs1719146, a SNP in exon 2 of CCL4, in 
the Black populations examined in the Modi et al. (2006) study was 3%, in our South African Black 
cohort, it was present at a frequency of 13%. The SNP rs1719153 is found in the region just 
downstream from the 3’UTR and the T allele occurs at frequencies of 11% and 28% in Black and 
Caucasian populations investigated in this study, respectively.  In the cohorts examined by Modi et al. 
(2006), the frequency of the allele was 0.7% and 23% for Black and Caucasian individuals respectively.  
Interestingly, rs1717146 forms part of the CCL4-SA-HapB1 haplotype described in the Black population 
and rs1719153 forms part of both the CCL4-SA-HapB2 and CCL4-SA-HapC1 haplotypes identified in the 
Black and Caucasian populations respectively.    
   
Since the CCL4 gene is so polymorphic, it was very difficult to associate differences in protein 
production with any single genetic variant or haplotype. In the Caucasian population many individuals 
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had more than one of the characterised haplotypes and therefore teasing apart which individuals to 
compare with each other with respect to protein produced was difficult.  Of the four deletions 
identified, rs3216921, a three base pair deletion downstream from the 3’UTR, was the most frequent 
deletion and the only one identified in Caucasian individuals. It was not found in the Black cohort.  
Individuals with this deletion had a significantly higher level of CCL4 protein production than those 
who did not harbour the deletion. The finding that LTNP individuals have a lower level of CCL4 
production than HIV-1-uninfected individuals brings to mind the question of whether having an 
increased level of CCL4 production is desirable in the context of HIV-1. Perhaps an elevated level of 
the CC-chemokine is protective against HIV-infection but, post infection, maybe a decreased level of 
CCL4 production will lead to slower disease progression.  It has been shown that it is only after a short 
period that viral levels in normally progressing individuals begin to differ from those of LTNPs, in other 
words, LTNPs are just better at controlling infection from that point forward (Vesanen et al. 1996).  It 
would be interesting to investigate whether the rs3219621 indel, associated with higher CCL4 
production in Caucasians, plays any role in HIV-1 susceptibility and/or control in HIV-1 infected 
Caucasian individuals. 
 
Single nucleotide polymorphisms in the CCL3L encoding genes were suggested to be useful indicators 
around which to build the copy number determination assays, for example if SNPs can distinguish 
between the non-allelic isoforms (Perry et al. 2014). From our experience of SNPs interfering in probe 
and primer binding sites, we feel that this is a valid point. Secondly, it was our initial intention to 
separately amplify the CCL4L1 and CCL4L2 genes. The challenge in primer design was not only in trying 
to find regions that were different enough to place the primers but, because the gene is not as well 
studied, the reference sequences for CCL4L2 were amended by the addition of a ‘fix patch,’ which 
corrected a difference reported between CCL4L1 and CCL4L2 in the region in which our primers were 
designed. Furthermore, other sites that did not share sequence similarity between the genes were 
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listed in dbSNP as polymorphic sites as some sequencing data that was submitted was probably 
generated by sequencing these genes together rather than separately. A similar problem was 
encountered by Paximadis et al. (2009) when trying to distinguish haplotypes in the CCL3L encoding 
genes. 
 
 One strategy that we are currently working on to get an idea of the genetic diversity of the CCL4L 
genes individually, is to use the copy number data that we generated to identify individuals with zero 
copies of either CCL4L1 or CCL4L2 and thereby sequence and study the CCL4L gene that is present.  It 
is predicted that if these genes are quite polymorphic, haplotype prediction would be difficult due to 
the multiple copy numbers, however, from our preliminary (5 CCL4L1 and 22 CCL4L2 sequences) 
analysis it appears that there is significantly less variation in these genes compared to CCL4 (data not 
shown),as well as compared to the CCL3L genes.  The low level of variations in these CCL4L genes may 
suggest differential selection for these genes.    
 
A recent study has demonstrated that a microRNA (miR-125b) downregulates CCL4 expression and 
plays a part in the increased levels of CCL4 seen in older individuals (Cheng et al. 2015). The role of 
miR-125b in regulation of CCL4 expression was confirmed by deleting the predicted microRNA binding 
site in the 3’UTR of CCL4 (Cheng et al. 2015).  While we did not find differences in CCL4 levels when 
individuals of both populations were stratified by age (perhaps relooking at this factor in a larger 
cohort would be beneficial), we did identify three 3’UTR SNPs in the CCL4 gene (two in Black 
individuals and one in Caucasian individuals). While none of these SNPs are predicted to cause a 
disruption in the miR-125b binding site (www.microRNA.org (Betel et al. 2008)), they are predicted to 
disrupt other microRNA sites (data not shown). This warrants further investigation into expression of 
miR-125b and the genetic characteristics of CCL4 3’UTRs in Black and Caucasian South African LTNP 
individuals, who have lower levels of CCL4 protein than their HIV-1-uninfected counterparts. Cheng et 
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al. (2015) suggest that the observed association between this microRNA and increased CCL4 
expression with age may be as a result of interference with miR-125b maturation. This finding prompts 
the question of whether LTNP individuals are somehow able to maintain a lowered expression of CCL4 
and if this may influence their progression in HIV-1-infection.  
 
To conclude, in this study we have shown that droplet digital PCR proved to be a far superior method 
for the copy number assessment of the genes CCL4L, CCL4L1 and CCL4L2 compared to qPCR. While 
results generated by both assays were comparable for lower copy numbers, as observed in the 
Caucasian population, at higher copy numbers, as observed in the Black population, the qPCR assay 
fared poorly compared to ddPCR. The incorporation of ddPCR as the standard method of assessing 
gene copy number in the future would potentially generate unambiguous, accurate copy number data 
that would contribute to the understanding of copy number variation and its contribution to human 
infection and disease. We have also shown that although the CCL3- and CCL4-encoding genes are 
found on the same segmental duplication and bind to the same receptor, their copy numbers vary 
from each other and the extent of this variation is dependent on the population being studied. In 
addition we have highlighted differences in production of these two chemokines.  We have shown 
that CCL4L gene copy number in the two South African populations does not directly influence 
chemokine production although, in the Black population, it was demonstrated that optimum CCL4 
production occurs when an individual possessed a CCL4L copy number equal to the population specific 
median, suggesting that instead of a gene dosage mechanism, that there may be much more complex 
mechanisms of regulation involved.  We further demonstrate the population differences exist 
between the South African Black and Caucasian cohorts with regards to the CCL4-encoding genes. 
Variation in key immune-modulating factors between populations needs to be kept in mind during the 
design of HIV-1 treatments or vaccines, as they may influence responses to these compounds, 
necessitating the conduction of drug and vaccine trials in diverse populations. By including a small 
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subset of LTNPs, individuals who inherently control HIV-1 infection for many years in the absence of 
antiretroviral therapy, we have had a glimpse into how studying these individuals can help to identify 
possible correlates of immunity against HIV-1. A greater understanding of host responses to HIV-1 will 
offer more criteria for the inclusion and exclusion of some strategies and help direct the search for 
treatments and cures down a better defined path. Investigations into the genetic variability of the 
CCL4 gene revealed the region to be very polymorphic with very clear population specific differences. 
We observed that variants along the entire CCL4 gene and its flanking region were organised in distinct 
haplotypes in both Caucasian and Black individuals with Caucasians exhibiting much stronger LD across 
the gene compared to Black individuals. We found an association between a three bp deletion in the 
Caucasian population and increased production of CCL4.  These findings highlight the need to carry 
out detailed genetic studies, as many novel genetic influences on protein production are still 
undiscovered as well as the need to keep population genetics in mind when trying to uncover these 
associations. This work has provided an important baseline and has influenced new directions of 
thought from which we can proceed to further investigate the impact of population specific variability 
on host immune factors and how these influence the outcomes of HIV-infection.  
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APPENDIX A: SUPPLEMENTARY DATA FOR CHAPTER 2 
 
Table: CCL4 sequencing primers 
Name Primer Sequence 5’ to 3’ 
Seq1 AGCAGTCTATCAGTCAACGG  
Seq2 TCCCTCCTCACATCCAAT 
Seq3 ACCACTTCCCTTTTCTTCTCGCCT 
Seq4 ACTGTCCTGTCTCTCCTCAT 
Seq5 TGTTCAAGCAAGCCCCTGT 
Seq6 CTGCTTTTCTTACACTGCGAGG 
Seq7 TCAGAGGACAGGGAAGCA 
Seq8 AATCTGTCCGCTCCTTGTTC 
Seq9 CCACTGTCACTGTTTCTCTGCT 
Seq10 TAAGGAAACAGAGGCACAGA 
Seq11 CCATCATAGGACCAGGCA 
Seq12 ATGGGACACAGACTCGTAG 
Seq13 CACTTCTCTGGGGTCAACA 
Seq14 GTTCCTGAGTCACACTA 
 
 
Table: CCL4 indel primers 
 
 
 
 
 
 
 
Name Primer Sequence 5’ to 3’ 
Indel1 ACAAGCCTGACCCCAAGAAC 
Indel2 ATCTCCCCATTCCCTGCCA 
Indel3 CAGTAGATTGGGATTAGAGTGC 
Indel4 GAACTGTGCTGCTCTTGGTGG 
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APPENDIX B: SUPPLEMENTARY DATA FOR CHAPTER 3 
 
 
Figure: Correlation of copy number generated by ddPCR and qPCR in the South African Black and Caucasian 
cohort for A: CCL4L, B: CCL4L1, C: CCL4L2. 
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APPENDIX C: AMINO ACID CODES  
 
 
A  alanine   Ala 
C  cysteine   Cys 
D  aspartate  Asp 
E  glutamate  Glu 
F  phenylalanine   Phe 
G  glycine    Gly 
H  histidine   His 
I  isoleucine   Iso 
K lysine    Lys 
L leucine    Leu 
M methionine   Met 
N  asparagine  Asp 
P  proline    Pro 
Q glutamine  Glu 
R  arginine   Arg 
S  serine    Ser 
T  threonine   Thr 
V  valine   Val 
W  tryptophan  Trp 
Y  tyrosine   Tyr 
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